select count(*) as counts from cancer where lower(`biomolecule`) LIKE '%rna%' && lower(`biomolecule`) NOT LIKE 'mirna%'

Browse Biomarkers Based on Biomolecules

This page shows data for RNA biomolecule.
Total Entries Retrieved: 507
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
14 MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
15 MGC5466+CHAF1A+CDS2+IER3 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
16 PPFIA3+COPEB+FOS+JUNB+ZFP36 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p=0.001 Tissue 15067324
17 MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2+CHAF1A+CDS2+IER3+PPFIA3+COPEB+FOS+JUNB+ZFP36 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
19 XLKD1/LYVE1 mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
20 CGA mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
21 F2R/PAR1 mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
22 BCL-G mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
23 XLKD1/LYVE1+CGA+ F2R/PAR1+ BCL-G mRNA Humans Differentially Expressed Prognostic Patients with Relapse Vs Without Relapse p<0.05 Tissue 14654526
29 Alpha Methylacyl Coenzyme A Racemase (AMACR) mRNA Humans Upregulated in Localised Prostate Cancer (3.1 fold) Diagnostic Benign Prostate vs Localised Prostate Cancer p<0.001 Tissue 11926890
30 Alpha Methylacyl Coenzyme A Racemase (AMACR) mRNA Humans Upregulated in Metastatic Prostate Cancer (1.67 fold) Diagnostic Benign Prostate vs Metastatic Prostate Cancer p<0.004 Tissue 11926890
43 Fatty Acid Synthase (FAS) mRNA Humans Upregulated in PCa (3 fold) [Mean Value: PCa:158 Vs Normal: 53] Diagnostic Prostate Cancer Vs Normal Adjacent p<0.00000029 Tissue 12939396
44 Fatty Acid Synthase (FAS) mRNA Humans Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8] Prognostic Gleason Score 7 Vs Metastatic Tumor p<0.00000029 Tissue 12939396
50 GalNAc-T3+PSMA+Hepsin+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
51 PSMA+Hepsin+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
52 GalNAc-T3+Hepsin+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
53 GalNAc-T3,+Hepsin+PSMA mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
54 GalNAc-T3+PSMA+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
55 DDR/PCA3 mRNA Humans Upregulated (140 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.007 Tissue 15609297
56 HEPSIN mRNA Humans Upregulated (21 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.049 Tissue 15609297
57 PSMA mRNA Humans Upregulated (66 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.047 Tissue 15609297
58 GalNAc-T3 mRNA Humans Upregulated (4.6 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.005 Tissue 15609297
70 AMACR (o-methylacyl-CoA racemaÌŠse) mRNA Humans Upregulated in PCa (3.3 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
71 SIM2 (single-minded homolog 2) mRNA Humans Upregulated in PCa (2.3 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
72 EST (similar to cDS4 retroviral related polyprotein) mRNA Humans Upregulated in PCa (2.3 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
73 EST (weakly similar to protease) mRNA Humans Upregulated in PCa (2.2 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
74 TRGV9 (Tcell receptory variable 9) mRNA Humans Upregulated in PCa (2.1 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
75 EST (AGR2 anterior gradient 2 homolog) mRNA Humans Upregulated in PCa (2.1 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
76 HPN (hepsin transmembrane protease, serine I) mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
77 KCNA5 (potassium voltage-gated channel), mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
78 TM4SF13 (transmembrane 4 superfamily member 13) mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
79 SOX9 (SRY sex determining region Y-box 9) mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
80 SOX4 (SRY sex determining region Y-box 4) mRNA Humans Upregulated in PCa (1.9 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
81 SLC26A2 (solute carrier family 26 member 2) mRNA Humans Upregulated in PCa (1.9 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
82 SYNP02 (synaptopodin) mRNA Humans Downregulated in PCa (4.2 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
83 SLC18A2 (solute carrier family 18 member 2) mRNA Humans Downregulated in PCa (3.0 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
84 CALD1 (caldesmon 1) mRNA Humans Downregulated in PCa (2.8 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
85 MRE11A (meiotic recombination 11 homologue A) mRNA Humans Downregulated in PCa (2.8 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
86 KRT15 (keratin 15) mRNA Humans Downregulated in PCa (2.7 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
87 ACTG2 (actin gamma 2 smooth muscle, enteric) mRNA Humans Downregulated in PCa (2.5 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
88 DSIPI (delta sleep inducing peptide, immunoreactor) mRNA Humans Downregulated in PCa (2.5 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
89 SLC18A2 (solute carrier family 18 member 2) mRNA Humans Downregulated in PCa (2.5 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
90 MME [membrane metallo-endopeptidase] mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
91 KRT17 (similar to keratin 17) mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
92 LY96 (lymphocyte antigen 96) mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
93 SYNP02 (synaptopodin) mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
101 bromo domain containing protein 2 (BRD2),+eukaryotic translation initiation factor 4 gamma 1 (EIF4G1)+ribosomal protein L22 (RPL22)+ribosomal protein L13a (RPL13a)+17 other autoantibodies mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Controls p<0.05 Serum 16177248
102 Methylation status of GSTP1 mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression p<0.03 Tissue 16322291
103 Methylation status of GSTP1 mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression P = 0.004 Tissue 16322291
104 Methylation status of APC mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression P = 0.004 Tissue 16322291
105 Methylation status of GSTP1 mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression P = 0.01 Tissue 16322291
106 Methylation status of Cyclin D2 + APC mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression 0.01 Tissue 16322291
114 PCDH7, NRXN3, TPTE/ PTEN2, EPHA3, TSPY, HGF, PKIA, PRLR, NR2F1, TNS, MET, CALN1, ADAM-TS3, NPL4, MYO3A, GNA11, GAGEB1/PA GE1, AKAP9, TCF4, MYLK, KLK2, HOXA10, DDR2, EGF, TEM8, XAGE-1, GAS2. mRNA Humans Upregulated (Log2 fold change: 2-7.9 fold) Prognostic Androgen Independent PCa Vs Androgen Dependent PCa NA Cell Lines 17977648
115 ANGPT2, THBS1, CCL5, PTK6, CXCL11, S100P, PSMD5, CDKN2B, PEG3, HTATIP2, CXCL2, RND1, NK4, ACPP, ICAM1, FOSL2, SFN, PLAT, INHBE, CDKN1C, TP73, SOCS2, BMPR1B, CCL2, VIM, SPRY2, CXCL10, LCN2, AKAP12, KLF4, ATF3, FBN1, TWIST1, ALCAM, MSX2, LOX, BTG1, SOCS1, PPP3CA, PPP3CA mRNA Humans Downregulated (Log2 fold change: 1.3-7.8 fold) Prognostic Androgen Independent PCa Vs Androgen Dependent PCa NA Cell Lines 17977648
116 PP2A mRNA Humans Downregulated in PCa Diagnostic Benign Prostatic Hyperplasia (BPH) vs Prostate Cancer (PCa) p=0.0073 Tissue 17977648
134 Fusion Status of TMPRSS2-ERG mRNA Humans Fusion of the genes in Positive Biopsy PCa Prognostic Positive Vs Negative Biopsies for PCa NA Urine 17785564
135 PCA3 mRNA Humans Upregulated in Positive Biopsy PCa Prognostic Positive Vs Negative Biopsies for PCa NA Urine 17785564
136 Fusion Status of (TMPRSS2-ERG)+PCA3 mRNA Humans Fused/ Upregulated in PCa Diagnostic Positive Vs Negative Biopsies for PCa NA Urine 17785564
138 CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1 mRNA Humans Upregulated GEX score in PCa Patients (PCa: 7.38 ± 0.35 Vs Non Cancer: 7.2±0.16) Diagnostic No Cancer Vs Prostate Cancer p=0.0013 Tissue 17459658
139 CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1 mRNA Humans Increased GEX Score with relapse Prognostic Relapse Vs No Relapse p=0.007 Tissue 17459658
159 AMACR (α-methylacyl-CoA racemåse) [AMACR 2094, 2097, 2098, 2095] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.12E-08 Tissue 16618727
160 PYCR1 (Pyroline 5 - Carboxylate reductase1) mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 8.58E-10 Tissue 16618727
161 MYO6 (Myosin VI) [MYO6-0041] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.15E-08 Tissue 16618727
162 SMPDL3B (Sphingomyelinase like phosphodiesterase 3B) [SMPDL3B 2030] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.32E-08 Tissue 16618727
163 NOX4 (NADPH oxidase 4) [NOX4 1355] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.57E-07 Tissue 16618727
164 FASN (Fatty Acid Synthase) [FASN 1432,1433, 1435] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 4.78E-05 Tissue 16618727
165 CACNA1D (Voltage-dep. L-type Calcium Channel Alpha 1D Subunit) [CACNA1D 2040, 2039] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.32E-06 Tissue 16618727
166 FBP1 (Fructose 1,6 Bisphosphatase 1) [FBP1 0807] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.46E-07 Tissue 16618727
167 IMPDH2 (Inosine-5′-monophosphate dehydrogenase 2) [IMPDH2 0144,0145] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.68E-05 Tissue 16618727
168 ABCC4 (Multidrug Resistance-Associated Protein 4) [ABCD4 2013] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.09E-05 Tissue 16618727
169 GART (Phosphoribosylglycinamide Formyltransferase) [GART 0310, 0307] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.57E-05 Tissue 16618727
170 CLN3 (ceroid lipofuscinosis, neuronal 3, juvenile) [CLN3 1132] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.50E-05 Tissue 16618727
171 DHPS (Deoxyhypusine Synthase) [DHPS 2028] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.68E-05 Tissue 16618727
172 BIRC5 (Baculoviral IAP Repeat Containing 5 (survivin)) [BIRC5 0847] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.73E-05 Tissue 16618727
173 REPS2 (RALBP1 Associated Eps Domain Containing 2) [REPS2 0732, 0733] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.18E-05 Tissue 16618727
174 RPS2 (40S Ribosomal Protein S2) [RPS2-0809] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.051607 Tissue 16618727
175 TMSNB (Thymosin, Beta, identified in neuroblastoma cells) [TMSNB 0227] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.34E-05 Tissue 16618727
176 EPB41 (Erythrocyte Membrane Protein Band 4.1) [EPB41 1096,1092] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.69E-05 Tissue 16618727
177 GCNT1 (Core 2 Beta1,6 N-Acetylglucosaminyltransferase-I) [GCNT1 0981, 0982,0985] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 8.15E-05 Tissue 16618727
178 LYPLA1 (Lysophospholipase 1) [LYPLA1 0862, 0860] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.006744 Tissue 16618727
179 RET1 (Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret) [RET1 0252 0250] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.008659 Tissue 16618727
180 HSPD1 (Heat Shock 60kDa Protein 1 (Chaperonin)) [HSPD1 0152, 0154] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.033554 Tissue 16618727
181 MAPT (Microtubule Associated Protein Tau) [MAPT 1060] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.000885 Tissue 16618727
182 C7ORF24 (Chromosome 7 Open Reading Frame 24) [C7ORF24 0.001028] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001028 Tissue 16618727
183 ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3) [ERBB3 1431] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001238 Tissue 16618727
184 PLA2G2A (Phospholipase A2 Group IIA) [PLA2G2A 1380] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001569 Tissue 16618727
185 NME1 (Nucleoside Diphosphate Kinase A) [NME1 0827] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001945 Tissue 16618727
186 CDK7 (Cyclin Dependent Kinase 7) [CDK7 0899] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.002319 Tissue 16618727
187 MMP9 (Matrix Metallopeptidase 9) [MMP9 1185] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.00262 Tissue 16618727
188 BGN (Biglycan) [BGN 1274] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.002956 Tissue 16618727
189 PPIB (Peptidylprolyl Isomerase B (Cyclophilin B)) [PPIB 0969] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.006963 Tissue 16618727
190 IQGAP2 (IQ Motif Containing GTPase Activating Protein 2) [IQGAP2 0234] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.010253 Tissue 16618727
191 DKFZP564B167 (DKFZP564B167 Protein) [DKFZP564B167 0717] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.015526 Tissue 16618727
192 TMEPAI (Transmembrane Prostate Androgen- Induced Protein) [TMEPAI 2074] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.023696 Tissue 16618727
193 STAC (SH3 And Cysteine Rich Domain) [STAC 1045, 1044, 1047] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 4.42E-07 Tissue 16618727
194 FGFR2 (Fibroblast Growth Factor Receptor 2) [FGFR2 0101,0095,0100,0106, 0107, 0097] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.42E-07 Tissue 16618727
195 CDC42BPA (CDC42 Binding Protein Kinase Alpha) [CDC42BPA 1051] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.56E-08 Tissue 16618727
196 KRT15 (keratin 15) [KRT15 1335, 1333, 1334,1341] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.60E-06 Tissue 16618727
197 TRIM29 (Tripartite Motif Containing 29) [TRIM29 1353, 1348, 1346] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 4.38E-06 Tissue 16618727
198 CES1 (Carboxylesterase ) [CES1 0942, 0937] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.43E-05 Tissue 16618727
199 CLU (Clusterin) [CLU 0196, 0192, 0191] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.000272 Tissue 16618727
200 ALDH1A2 (Aldehyde Dehydrogenase 1A2) [ALDH1A2 0004,0001, 0006] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.000266 Tissue 16618727
201 DRR1 (Collagen and Wnt5a regulated receptor tyrosin kinase) [DRR1 - 0753] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.88E-07 Tissue 16618727
202 ROBO1 (Roundabout, Axon Guidance Receptor, Homolog 1) [ROBO1 1419] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.26E-07 Tissue 16618727
203 LTBP4 (Latent TFG Beta Binding Protein 4) [LTBP4 0752, 0747, 0742, 1519, 1518, 0745, 0748, 0746] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.002361 Tissue 16618727
204 PGR (Progesterone Receptor) [PGR 1161, 1162] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.77E-06 Tissue 16618727
205 EDNRB (Endothelin Receptor Type B) [EDNRB 1187] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.88E-06 Tissue 16618727
206 ANGPT1 (Angiopoietin 1) [ANGPT1 1032, 1031] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.72E-05 Tissue 16618727
207 IGF1 (Insulin like Growth Factor 1 Somatomedin C) [IGF1 0025] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.77E-06 Tissue 16618727
208 COL6A2 (Collagen, Type VI, Alpha 2) [COL6A2 1489] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 8.16E-06 Tissue 16618727
209 PTGDS (Prostaglandin D2 Synthase 21kDa) [PTGDS 0787] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.09E-05 Tissue 16618727
210 ANGPTL2 (Angiopoietin-related Protein 2) [ANGPTL2 0950] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.20E-05 Tissue 16618727
211 VCL (Vinculin) [VCL 1534, 0933, 0936] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.011744 Tissue 16618727
212 GSTP1 (Glutathione S-transferase P) [GSTP1 0927, 0923] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.030854 Tissue 16618727
213 SAT (Spermidine/Spermine N1-acetyltransferase) [SAT 0840, 0842] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.052888 Tissue 16618727
214 TGFB2 (Transforming Growth Factor, Beta 2) [TGFB2 0085] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.095398 Tissue 16618727
215 Endothelial cell-specific molecule 1; Protein tyrosine phosphatase receptor type-Q, CD24 antigen; Gap junction membrane channel protein alpha 1; Transmembrane 4 superfamily member 3; Serpine2; Activated leukocyte cell adhesion molecule; Fibromodulin; Plasminogen activator inhibitor 2 type A; Kelch repeat and BTB (POZ) domain containing 10 (krp1); Preproenkephalin, related sequence; Sialophorin; Thymosin beta-4; Glutamate receptor interacting protein 1; Synuclein, gamma; Hypoxanthine guanine phosphoribosyl transferase; Phosphoribosyl pyrophosphate synthetase 1; Phosphoribosyl pyrophosphate synthetase 2; UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6; Dual specificity phosphatase 5; Cytochrome P450, family 3, subfamily a, polypeptide 13; 3-hydroxy-3-methylglutaryl-Coenzyme A reductase ; Branched chain keto acid dehydrogenase E1, beta polypeptide; Cytochrome P450, subfamily 24; Plasminogen activator, urokinase; Caveolin 1; Cyclin D1; High mobility group AT-hook 1; Cxxc5; HNF-3/forkhead homolog-1; Fatty acid binding protein 4, adipocyte; Fatty acid binding protein 5, epidermal; Rabin 3; Phospholipase C, delta 4; Decay-accelarating factor; Coagulation factor II (thrombin) receptor-like 1; Nerve growth factor receptor associated protein 1; Asparagine synthetase; Dual specificity phosphatase 6; Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform; Protein tyrosine phosphatase, receptor type, N1; UDP glycosyltransferase 1 family polypeptide A2; Adenosine monophosphate deaminase 3; Stearoyl-Coenzyme A desaturase 1; Hypothetical LOC290595 (LOC290595), mRNA; Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA; Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA; Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds; mRNA Rat Upregulated (Endothelial cell-specific molecule 1 (26.5 fold); Protein tyrosine phosphatase receptor type Q (19.72 fold); CD24 antigen (15.56 fold); Gap junction membrane channel protein alpha 1 (10.53 fold); Transmembrane 4 superfamily member 3 (10.4 fold); Serpine2 (8.61 fold); Activated leukocyte cell adhesion molecule (6.65 fold) ; Fibromodulin (2.62 fold); Plasminogen activator inhibitor 2 type A (2.11 fold); Kelch repeat and BTB (POZ) domain containing 10 (krp1) (36.21 fold); Preproenkephalin, related sequence (24.63 fold); Sialophorin1 (24.14 fold); Thymosin beta-4 (19.82 fold) ; Glutamate receptor interacting protein 1 (8.4 fold) ; Synuclein, gamma (6.62 fold); Hypoxanthine guanine phosphoribosyl transferase (11.45 fold); Phosphoribosyl pyrophosphate synthetase 1 (8.25 fold) ; Phosphoribosyl pyrophosphate synthetase 2 (5.37 fold); UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6 (3.4 fold); Dual specificity phosphatase 5 (2.35 fold); Cytochrome P450, family 3, subfamily a, polypeptide 13 (14.28 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (3.49 fold) ; Branched chain keto acid dehydrogenase E1, beta polypeptide (2.14 fold); Cytochrome P450, subfamily 24 (2.11 fold); Plasminogen activator, urokinase (4.68 fold); Caveolin 1 (31.05 fold) ; Cyclin D1 (7.95 fold); High mobility group AT-hook 1 (15.41 fold) ; Cxxc5 (4.25 fold); HNF-3/forkhead homolog-1 (3.08 fold); Fatty acid binding protein 4, adipocyte (34.02 fold); Fatty acid binding protein 5, epidermal (15.38 fold) ; Rabin 3 (6.46 fold); Phospholipase C, delta 4 (2.64 fold); Decay-accelarating factor (4.02 fold); Coagulation factor II (thrombin) receptor-like 1 (4.96 fold); Nerve growth factor receptor associated protein 1 (8.75 fold); Asparagine synthetase (14.65 fold); Dual specificity phosphatase 6 (11.08 fold); Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform (2.31 fold) ; Protein tyrosine phosphatase, receptor type, N1 (2.22 fold); UDP glycosyltransferase 1 family polypeptide A21 (5.93 fold); Adenosine monophosphate deaminase 3 (2.14 fold); Stearoyl-Coenzyme A desaturase 1 (25.92 fold); Hypothetical LOC290595 (LOC290595), mRNA (8.46 fold); Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA (4.76 fold); Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA (3.58 fold); Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds (3.38 fold); Prognostic MAT-LyLu Vs G Cell Lines p<0.005 Cell Lines 17713630
216 Procollagen, type XII, alpha 1; Glycoprotein Ib (platelet), beta polypeptide; Macrophage stimulating 1 (hepatocyte growth factor-like); Alpha-2-macroglobulin; Hyaluronan and proteoglycan link protein 1; Glycoprotein 38; Decorin; Vascular cell adhesion molecule 1; Clusterin; Elastin; Biglycan; Selenoprotein P, plasma, 1; T-cell receptor gamma chain; Myxovirus (influenza virus) resistance 2; Major histocompatibility complex, class II, DM alpha; MHC class Ib RT1.S3; RT1 class Ib, locus Aw2; Similar to interferon regulatory factor 7 (LOC293624), mRNA; Late gestation lung protein 1; Transgelin; Ectonucleoside triphosphate diphosphohydrolase 2; Dual specificity phosphatase 1; Cytochrome b-245, alpha polypeptide; 3-alpha-hydroxysteroid dehydrogenase; Cathepsin S; Alanyl (membrane) aminopeptidase; Dipeptidase 1 (renal); Caspase 1; B-cell translocation gene 3; CD 81 antigen; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; LIM homeobox protein 2; Lectin, galactose binding, soluble 9; apolipoprotein E; Ubiquitin carboxy-terminal hydrolase L1; Parvalbumin; Purkinje cell protein 4; Carboxylesterase 1; O-6-methylguanine-DNA methyltransferase; UDP glycosyltransferase 1 family, polypeptide A6; Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5; Growth hormone receptor; Insulin-like growth factor 1; Insulin-like growth factor binding protein 5; Peripherin 1; Arginosuccinate synthetase; Lactate dehydrogenase B; Calcium/calmodulin-dependent serine protein kinase; Aminolevulinic acid synthase 1; 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2; Alcohol Dehydrogenase 1; Phosphodiesterase 3B; Similar to kelch domain containing 3; testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA; Similar to cornichon-like protein (LOC361705), mRNA; Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA; Similar to CLN6 protein (LOC315746), mRNA; Reticulocalbin 3; Similar to CG31613-PA (LOC364716), mRNA; mRNA Rat Downregulated (Procollagen, type XII, alpha 1 (2.18 fold); Glycoprotein Ib (platelet), beta polypeptide (2.5 fold); Macrophage stimulating 1 (hepatocyte growth factor-like) (2.61 fold); Alpha-2-macroglobulin (3.8 fold); Hyaluronan and proteoglycan link protein 1 (3.82 fold); Glycoprotein 38 (3.87 fold); Decorin (5.74 fold); Vascular cell adhesion molecule 1 (7.82 fold); Clusterin (8.84 fold); Elastin (12.76 fold); Biglycan (13.23 fold); Selenoprotein P, plasma, 1 (23.08 fold); T-cell receptor gamma chain (2.2 fold); Myxovirus (influenza virus) resistance 2 (2.22 fold) ; Major histocompatibility complex, class II, DM alpha (2.37 fold); MHC class Ib RT1.S3 (4.8 fold) ; RT1 class Ib , locus Aw2 (5.18 fold); Similar to interferon regulatory factor 7 (LOC293624), mRNA (6.14 fold); Late gestation lung protein 1 (2.26 fold); Transgelin (5.72); Ectonucleoside triphosphate diphosphohydrolase 2 (2.7 fold); Dual specificity phosphatase 1 (2.3 fold); Cytochrome b-245, alpha polypeptide (3.64 fold); 3-alpha-hydroxysteroid dehydrogenase (4.86 fold); Cathepsin S (2.33 fold); Alanyl (membrane) aminopeptidase (3.18 fold); Dipeptidase 1 (renal) (6.82 fold); Caspase 1 (11.12 fold); B-cell translocation gene 3 (17.35 fold); CD 81 antigen (36 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.28 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.62 fold); LIM homeobox protein 2 (5.43 fold); Lectin, galactose binding, soluble 9 (2.46 fold); apolipoprotein E (29.52 fold); Ubiquitin carboxy-terminal hydrolase L1 (16.29 fold); Parvalbumin (3.85 fold); Purkinje cell protein 4 (6.82 fold); Carboxylesterase 1 (2.16 fold); O-6-methylguanine-DNA methyltransferase (4.62 fold); UDP glycosyltransferase 1 family, polypeptide A6 (3.25 fold); Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5 (2.27 fold); Growth hormone receptor (3.12 fold); Insulin-like growth factor 1 (4.85 fold); Insulin-like growth factor binding protein 5 (5.25 fold); Peripherin 1 (7.17 fold); Arginosuccinate synthetase (12.75 fold); Lactate dehydrogenase B (15.07 fold); Calcium/calmodulin-dependent serine protein kinase (4.13 fold); Aminolevulinic acid synthase 1 (2.39 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (3.17 fold); Alcohol Dehydrogenase 1 (6.38 fold); Phosphodiesterase 3B (4.76 fold); Similar to kelch domain containing 3 testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA (2.17 fold); Similar to cornichon-like protein (LOC361705), mRNA (2.35 fold); Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA (2.81 fold); Similar to CLN6 protein (LOC315746), mRNA (3.68 fold); Reticulocalbin 3 (3.94 fold); Similar to CG31613-PA (LOC364716), mRNA (8.61 fold); Prognostic MAT-LyLu Vs G Cell Lines p<0.005 Cell Lines 17713630
217 Kelch repeat and BTB (POZ) domain containing 10 (krp1) mRNA Rat Upregulated in MAT-LyLu (48 fold) Prognostic MAT-LyLu Vs G Cell Lines p=0.01816 Cell Lines 17713630
218 Endothelial cell-specific molecule 1 mRNA Rat Upregulated in MAT-LyLu (23 fold) Prognostic MAT-LyLu Vs G Cell Lines p=0.00995283 Cell Lines 17713630
219 Caveolin 1 mRNA Rat Upregulated in MAT-LyLu (45 fold) Prognostic MAT-LyLu Vs G Cell Lines p=0.0009527 Cell Lines 17713630
229 ENC1 + GJB1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
230 MYO6 + AMACR mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
231 TSPAN13 + PRKCBP1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
232 C20ORF74 + DAPK1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
233 IMAGE:396839 + ENC1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
234 Metaclassifier: ENC1+GJB1+MYO6+AMACR+TSPAN13+PRKCBP+C20ORF74+DAPK1+IMAGE:396839 + ENC1 mRNA Humans Differentially Expressed Prognostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
235 ARL6IP+MYH11 mRNA Humans Differentially Expressed Prognostic Primary Vs Metastatic Prostate Cancer NA Tissue 17460773
236 Cytokeratin 5 (CK5) mRNA Humans Upregulated in Dasatinib Sensitive Cell Lines (>3 fold) Potential Predictive Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines p<0.05 Cell Lines 18047674
237 Prostate Specific Antigen (PSA) mRNA Humans Downregulated in Dasatinib Sensitive Cell Lines (>3 fold) Potential Predictive Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines p<0.05 Cell Lines 18047674
238 Androgen Receptor (AR) mRNA Humans Downregulated in Dasatinib Sensitive Cell Lines (>3 fold) Potential Predictive Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines p<0.05 Cell Lines 18047674
243 SPINK1 mRNA Humans Upregulated in PCa Diagnostic Normal Vs Prostate Cancer p=0.0002 Urine 18245462
244 GOLPH2 mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=0.0002 Urine 18245462
245 PCA3 mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=0.001 Urine 18245462
246 SPINK1, PCA3, GOLPH2, TMPRSS2:ERG mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=1.91E-11 Urine 18245462
247 SPINK1, PCA3, GOLPH2, TMPRSS2:ERG mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=1.91E-11 Urine 18245462
248 PI3-K p85 α mRNA Humans Downregulated in Gleason Score 7-10 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
249 ILK mRNA Humans Downregulated in Gleason Score 7-11 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
250 PTEN mRNA Humans Downregulated in Gleason Score 7-12 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
251 PHLPP mRNA Humans Downregulated in Gleason Score 7-13 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
252 FOXO1A mRNA Humans Downregulated in Gleason Score 7-14 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
256 TOP2A mRNA Humans Upregulated in PCa (≥2 fold) Diagnostic Prostate Cancer Vs Nonneoplastic Sample p<0.05 Tissue 18347174
257 ERG mRNA Humans Upregulated in PCa (≥2 fold) Diagnostic Prostate Cancer Vs Nonneoplastic Sample p<0.05 Tissue 18347174
258 NRP1 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.007 Tissue 18347174
259 TOP2A mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p<0.0001 Tissue 18347174
260 RRM2 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p<0.0001 Tissue 18347174
261 KHRDSB3 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.015 Tissue 18347174
262 SSTR1 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.006 Tissue 18347174
263 Methylation Status of NKX2-5 mRNA Humans Hypermethylated (2.7% normal vs 14% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
264 Methylation Status of CALSTN1 mRNA Humans Hypermethylated (2.5% normal vs 12.1% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
265 Methylation Status of SPOCK2 mRNA Humans Hypermethylated (7.5% normal vs 15.2% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
266 Methylation Status of NSE1 mRNA Humans Hypermethylated (10.3% normal vs 20.5% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
267 Methylation Status of SLC16A12 mRNA Humans Hypermethylated (9% normal vs 22% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
268 Methylation Status of FOXN4 mRNA Humans Hypermethylated (2.4% normal vs 4.3% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
269 Methylation Status of GALR2 mRNA Humans Hypermethylated (2% normal vs 4.3% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
270 Methylation Status of DPYS mRNA Humans Hypermethylated (24.2% normal vs 42.71% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
271 Methylation Status of (DPYS or NKX2-5) mRNA Humans Hypermethylated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
272 Methylation Status of (CALSTN1 or DYPS) mRNA Humans Hypermethylated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
273 Methylation Status of (NSE1 or DPYS) mRNA Humans Hypermethylated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
274 Methylation Status of (NSE1 or SPOCK2) mRNA Humans Hypermethylated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
275 Methylation Status of (SLC16A12 or DPYS) mRNA Humans Hypermethylated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
276 Fusion Status of TMPRSS2:ERG mRNA Humans Increased fusion in patients with biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence p=0.0523 Tissue 18500259
277 Mutation of PTEN mRNA Humans Deletion found in patients with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence p=0.0009 Tissue 18500259
278 Fusion Status of TMPRSS2:ERG + PTEN deletion mRNA Humans Fusion + Deletion Prognostic Biochemical Recurrence Vs no Recurrence p=0.001 Tissue 18500259
279 Fusion Status of TMPRSS2:ERG + PTEN deletion mRNA Humans Fusion + Deletion Prognostic Biochemical Recurrence Vs no Recurrence p=0.036 Tissue 18500259
280 Golgi phosphoprotein 2 (GOLPH2) mRNA Humans Upregulated in Prostate Cancer(3.04 fold) Diagnostic prostate cancer Vs normal prostate p<0.001 Tissue 18543251
283 Myosin VI (MYO6) mRNA Humans Upregulated in Prostate Cancer Diagnostic Tumor and adjacent normal prostate tissues NA Tissue 18543251
379 TMPRSS2:ERG mRNA Humans Fused in Prostate Cancer Diagnostic Benign vs. PCA p<0.05 Expressed Prostatic Secretion 18948370
380 Serum PSA + DRE + Methylation Status of RARB mRNA Humans Hypermethylated in Prostate Cancer Diagnostic Benign vs. PCA p<0.06 Expressed Prostatic Secretion 18948370
381 Serum PSA + DRE + Methylation Status of (GSTP1, APC, RARB, and RASSF1) mRNA Humans GSTP1, APC, RARB, and RASSF1 Hypermethylated in Prostate Cancer Diagnostic Benign vs. PCA p<0.01 Expressed Prostatic Secretion 18948370
382 Serum PSA + DRE + Methylation Status of RASSF1 mRNA Humans RASSF1 Hypermethylated in Prostate Cancer Diagnostic Benign vs. PCA p< 0.05 Expressed Prostatic Secretion 18948370
383 Serum PSA + DRE + PCA3 mRNA Humans NA Diagnostic Benign vs. PCA p<0.01 Expressed Prostatic Secretion 18948370
384 Serum PSA + DRE + TMPRSS:ERG mRNA Humans NA Diagnostic Benign vs. PCA p<0.001 Expressed Prostatic Secretion 18948370
385 TMPRSS2:ERG mRNA Humans Fused in Prostate Cancer Prognostic (Benign Samples + Gleason sums < 7) Vs ≥ 7 p<0.05 Expressed Prostatic Secretion 18948370
386 Serum PSA + DRE + Methylation Status of GSTP1 mRNA Humans Hypermethylated in Prostate Cancer Diagnostic (Benign Samples + Gleason sums < 7) Vs ≥ 7 p<0.05 Expressed Prostatic Secretion 18948370
387 Serum PSA + DRE + Methylation Status of APC mRNA Humans Hypermethylated in Prostate Cancer Diagnostic (Benign Samples + Gleason sums < 7) Vs ≥ 7 p<0.01 Expressed Prostatic Secretion 18948370
388 Serum PSA + DRE + Methylation Status of RARB mRNA Humans Hypermethylated in Prostate Cancer Diagnostic (Benign Samples + Gleason sums < 7) Vs ≥ 7 p<0.01 Expressed Prostatic Secretion 18948370
389 Serum PSA + DRE + Methylation Status of RASSF1 mRNA Humans Hypermethylated in Prostate Cancer Diagnostic (Benign Samples + Gleason sums < 7) Vs ≥ 7 p<0.05 Expressed Prostatic Secretion 18948370
390 Serum PSA + DRE + Methylation Status of (GSTP1, APC, RARB, and RASSF1) mRNA Humans GSTP1, APC, RARB, and RASSF1 Hypermethylated in Prostate Cancer Diagnostic (Benign Samples + Gleason sums < 7) Vs ≥ 7 p<0.05 Expressed Prostatic Secretion 18948370
391 Serum PSA + DRE + PCA3 mRNA Humans NA Diagnostic (Benign Samples + Gleason sums < 7) Vs ≥ 7 p<0.01 Expressed Prostatic Secretion 18948370
392 Serum PSA + DRE + TMPRSS2:ERG mRNA Humans Fused in Prostate Cancer Diagnostic (Benign Samples + Gleason sums < 7) Vs ≥ 7 p<0.001 Expressed Prostatic Secretion 18948370
393 Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU) mRNA Humans Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC) Diagnostic Benign Vs Prostate Cancer Clusterin: p<0.01 Tissue 18974881
394 Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU) mRNA Humans Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 NA Tissue 18974881
406 Androgen Receptor (AR) mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (11 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
407 Androgen Receptor AR-V1 mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (22 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
408 Androgen Receptor AR-V7 mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (20 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
409 Androgen Receptor AR-V7 mRNA Humans Higher expression in patients with biochemical recurrence Prognostic PSA Recurrence Vs No PSA Recurrence p=0.012 Tissue 19117982
430 TMPRSS2 mRNA Humans Upregulated in PCa: (Normal: 0.26 ± 0.04 vs PCa: 3.91 ± 0.78) Diagnostic prostate cancer Vs Adjacent Normal p=0.001 Tissue 19242826
431 TMPRSS2 mRNA Humans Upregulated (Clinical Stage 1&2: 3.43 ± 0.62 ; Vs Clinical Stage 3: 5.45 ± 0.92) Prognostic Clincal Stage (1-2) Vs Clinical Stage 3 p=0.02 Tissue 19242826
432 TMPRSS2 mRNA Humans Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53) Prognostic Gleason Score ≤6, Vs Gleason Score>6 p=0.008 Tissue 19242826
433 TMPRSS2 mRNA Humans Upregulated (Tumor Grade 1-2: 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31) Prognostic Tumor Grade (1-2) Vs Tumor Grade 3 p=0.016 Tissue 19242826
434 KLK11 mRNA Humans Upregulated in PCa: (Normal: 0.49 ± 0.07 vs PCa: 3.63 ± 0.42) Diagnostic prostate cancer Vs Adjacent Normal p=0.003 Tissue 19242826
435 KLK11 mRNA Humans Upregulated (CS: (1-2) 6.05 ± 1.34 vs CS 3: 3.93 ± 0.45) Prognostic Clincal Stage (1-2) Vs Clinical Stage 3 p=0.009 Tissue 19242826
436 KLK11 mRNA Humans Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53) Prognostic Gleason Score ≤6, Vs Gleason Score>6 p=0.01 Tissue 19242826
437 KLK11 mRNA Humans Upregulated (Tumor Grade 1-2 : 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31) Prognostic Tumor Grade (1-2) Vs Tumor Grade 3 p=0.006 Tissue 19242826
442 ACPP; AD-017; AMIGO2; APPBP2; ASNS; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10; C1orf9; C22orf18 (CENPM); C5orf13; C6orf111; C6orf210; C9orf116; C9orf127; CATSPER2; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2; CDC20; CDC25C; CDC6; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1; EFNB2; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1; GALNT7; GFPT1; GGA2; GTSE1; GTSE1; H2AFX; H2AFY; HCAP-G; HCAP-G; HECA; HMGB2; HMMR; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A KLK2; KLK2; KLK3; KNS2; KNTC2; LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5 ; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10; MYRIP; NAP1L3; NAV3; NEK2; NEK2 NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A; PDIR; PER3; PIK3R1;PINK1; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B; RACGAP1; RBM30; RFC3; RRM1 ; RRM2; RRM2; SAS; SDC2 ; SDC2 ; SDC4; SEC6L1; SHCBP1 ; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2; STK3; STK6 ; TM4SF1; TMPO; TNFRSF10B ; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK; TPBG; TPX2; TRIB1; TTC3; TUBA3; TYMS; UAP1; UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT mRNA Humans Differentially Expressed Prognostic Metastatic Vs Localised Prostate Cancer p=0.0000121714 Cell Lines 19351846
443 ACPP; AD-017 ; AMIGO2; APPBP2; ASNS ; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10 ; C1orf9; C22orf18 (CENPM) ; C5orf13; C6orf111 ; C6orf210; C9orf116 ; C9orf127; CATSPER2 ; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2 ; CDC20; CDC25C ; CDC6 ; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1 ; EFNB2 ; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1 ; GALNT7; GFPT1 ; GGA2; GTSE1; GTSE1 ; H2AFX ; H2AFY; HCAP-G; HCAP-G ; HECA; HMGB2; HMMR ; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A; KLK2 ; KLK2 ; KLK3; KNS2 KNTC2 LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10 MYRIP; NAP1L3; NAV3 ; NEK2; NEK2; NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A ; PDIR; PER3 ; PIK3R1 ; PINK1 ; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B ; RACGAP1;RBM30; RFC3; RRM1; RRM2; RRM2; SAS ; SDC2; SDC2 ; SDC4; SEC6L1; SHCBP1; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2 ; STK3; STK6; TM4SF1 ; TMPO; TNFRSF10B; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK ; TPBG; TPX2; TRIB1 ; TTC3; TUBA3; TYMS; UAP1;UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT mRNA Humans Differentially Expressed Prognostic Androgen Dependent Vs Androgen Independent Prostate Cancer p=0.0056 Cell Lines 19351846
444 Differential display 3 (DD3/PCA3) mRNA Humans Upregulated in PCa (37 fold) Diagnostic Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa) p=0.0001 Urine 19489685
445 Urinary PSA mRNA Humans Upregulated Diagnostic Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa) p=0.0001 Urine 19489685
446 DD3 +PSA mRNA Humans Upregulated Diagnostic Benign prostatic hyperplasia (BPH) Vs prostate cancer (PCa) p<0.0001 Urine 19489685
474 CCNB1 (cyclin B1); CENPF (centromere protein F, 350/400 ka (mitosin)); BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)); CLDN4 (claudin 4); KIAA0101 (KIAA0101); LOC400879 (Hypothetical gene supported by AK096951); SLC39A6 (solute carrier family 39 (zinc transporter), member 6); SOX4 (SRY (sex determining region Y)-box 4); TOP2A (topoisomerase (DNA) II alpha 170 kDa) mRNA Humans Upregulated: CCNB1 (cyclin B1) [1.8 fold]; CENPF (centromere protein F, 350/400 ka (mitosin)) [1.4 fold]; BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)) [1.4 fold]; CLDN4 (claudin 4) [2.4 fold]; KIAA0101 (KIAA0101) [1.6 fold]; LOC400879 (Hypothetical gene supported by AK096951) [1.7 fold]; SLC39A6 (solute carrier family 39 (zinc transporter), member 6) [1.6 fold]; SOX4 (SRY (sex determining region Y)-box 4) [1.8 fold]; TOP2A (topoisomerase (DNA) II alpha 170 kDa) [1.7 fold] Diagnostic Tumor Vs Adjacent To Tumor p=0.05 Tissue 19652763
475 ABLIM3 (actin binding LIM protein family, member 3); AOX1 (aldehyde oxidase 1); CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)); DSCR1 (Down syndrome critical region gene 1); GLRX (glutaredoxin (thioltransferase)); IGFBP4 (insulin-like growth factor binding protein 4); MT1B (metallothionein 1B); MT1E (metallothionein 1E); MT1F (metallothionein 1F); MT1H (metallothionein 1H); C1QB (complement component 1, q subcomponent, B chain); CYB5R3 (cytochrome b5 reductase 3); DARC (Duffy blood group, chemokine receptor); DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)); F13A1 (coagulation factor XIII, A1 polypeptide); FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)); G0S2 (G0/G1switch 2); GAS6 (growth arrest-specifi c 6); IFITM2 (interferon induced transmembrane protein 2 (1–8D)); ITGA1 (integrin, alpha 1); MAP4 (microtubule-associated protein 4); MT1A (metallothionein 1A); MT2A (metallothionein 2A); PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase); PROS1 (protein S (alpha)); RBPMS (RNA binding protein with multiple splicing); RDX (Radixin); RNF11 (ring finger protein 11); S100A8 (S100 calcium binding protein A8); SERINC1 (serine incorporator 1); SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)); STOM (stomatin); TGFBR3 (transforming growth factor, beta receptor III); TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)); WDR47 (WD repeat domain 47) mRNA Humans Downregulated: ABLIM3 (actin binding LIM protein family, member 3) [1.6 fold]; AOX1 (aldehyde oxidase 1) [2.6 fold]; CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)) [1.7 fold]; DSCR1 (Down syndrome critical region gene 1) [1.6 fold]; GLRX (glutaredoxin (thioltransferase)) [1.7 fold]; IGFBP4 (insulin-like growth factor binding protein 4) [2.5 fold]; MT1B (metallothionein 1B) [2.3 fold]; MT1E (metallothionein 1E) [1.9 fold]; MT1F (metallothionein 1F) [2.3 fold]; MT1H (metallothionein 1H) [2.4 fold]; C1QB (complement component 1, q subcomponent, B chain) [1.4 fold]; CYB5R3 (cytochrome b5 reductase 3) [1.4 fold]; DARC (Duffy blood group, chemokine receptor) [2.9 fold]; DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)) [1.4 fold]; F13A1 (coagulation factor XIII, A1 polypeptide) [2.1 fold]; FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)) [1.6 fold]; G0S2 (G0/G1switch 2) [2.2 fold]; GAS6 (growth arrest-specifi c 6) [2 fold]; IFITM2 (interferon induced transmembrane protein 2 (1–8D)) [2 fold]; ITGA1 (integrin, alpha 1) [1.4 fold]; MAP4 (microtubule-associated protein 4) [1.6 fold]; MT1A (metallothionein 1A) [2.6 fold]; MT2A (metallothionein 2A) [2.5 fold]; PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase) [1.3 fold]; PROS1 (protein S (alpha)) [1.7 fold]; RBPMS (RNA binding protein with multiple splicing) [2.4 fold]; RDX (Radixin) [1.4 fold]; RNF11 (ring finger protein 11) [1.4 fold]; S100A8 (S100 calcium binding protein A8) [2.3 fold]; SERINC1 (serine incorporator 1) [1.5 fold]; SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)) [2.2 fold]; STOM (stomatin) [1.8 fold]; TGFBR3 (transforming growth factor, beta receptor III) [1.7 fold]; TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)) [1.8 fold]; WDR47 (WD repeat domain 47) [1.5 fold] Diagnostic Tumor Vs Adjacent To Tumor p=0.05 Tissue 19652763
486 PSGR (Prostate-Specific G-protein Coupled Receptor) mRNA Humans Upregulated Diagnostic Benign Vs Prostate Cancer p=0.008 Urine 20672322
487 PCA3 (Prostate Cancer Gene 3) mRNA Humans Upregulated Diagnostic Benign Vs Prostate Cancer p<0.001 Urine 20672322
488 PSGR + PCA3 mRNA Humans Upregulated Diagnostic Benign Vs Prostate Cancer NA Urine 20672322
489 PCA3 (Prostate Cancer Gene 3) mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive PCa Biopsy Vs Negative PCa Biopsy p <0.0001 Urine 20850153
490 Age+ Family History+ PCA3 + %fPSA+ Prostate Volume+ sPSA mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive PCa Biopsy Vs Negative PCa Biopsy p <0.0001 Urine 20850153
491 Age+ Family History+ PCA3 + %fPSA+ Prostate Volume+ sPSA mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive PCa Biopsy Vs Negative PCa Biopsy p <0.0001 Urine 20850153
503 ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1; mRNA Humans Differentially Expressed: ANXA5 [1.47 fold]; APLP2 [1.22 fold]; COL1A2 [1.18 fold]; CRIM1 [1.20 fold]; ECHS1 [1.18 fold]; HMGB1 [1.40 fold]; MAP3K5 [1.35 fold]; NGFRAP1 [1.32 fold]; NPM1 [1.30 fold]; NUB1 [1.12 fold]; PDIA3 [1.43 fold]; PLA2G2A [1.75 fold]; ROCK1 [1.17 fold]; TEGT [1.32 fold]; TMEM16G [0.66 fold]; TMEM69 [1.08 fold]; TRAF4 [1.26 fold]; VCAN [1.31 fold]; VCP [1.18 fold]; VDAC1 [1.51 fold]; Prognostic Gleason Score 6 Vs Gleason Score (8-10) p<0.05 Tissue 20035634
504 ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1; mRNA Humans Differentially Expressed: ANXA5 [4.28 fold]; APLP2 [2.83 fold]; COL1A2 [2.02 fold]; CRIM1 [3.23 fold]; ECHS1 [1.89 fold]; HMGB1 [4.68 fold]; MAP3K5 [2.98 fold]; NGFRAP1 [3.95 fold]; NPM1 [3.07 fold]; NUB1 [1.62 fold]; PDIA3 [2.40 fold]; PLA2G2A [3.00 fold]; ROCK1 [9.76 fold]; TEGT [2.77 fold]; TMEM16G [0.35 fold]; TMEM69 [2.77 fold]; TRAF4 [2.59 fold]; VCAN [2.92 fold]; VCP [2.75 fold]; VDAC1 [5.41 fold]; Prognostic Gleason Score 6 Vs Gleason Score (8-10) p<0.05 Tissue 20035634
505 MAP3K5 mRNA Humans Upregulated in Gleason Score 8-10 Prognostic Gleason Score 6 Vs Gleason Score (8-10) qRT-PCR: p=0.0129 Tissue 20035634
506 PDIA3 mRNA Humans Upregulated in Gleason Score 8-10 Prognostic Gleason Score 6 Vs Gleason Score (8-10) qRT-PCR: p=0.00167 Tissue 20035634
507 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in PCa Diagnostic Tumors Vs patient matched non-tumor NA Tissue 20043080
508 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in PCa (ratio = 1.94±0.256) Diagnostic Tumors Vs patient matched non-tumor p<0.01 Tissue 20043080
509 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in Metastatis (Metastatis: 1.81±0.153; Healthy: 1.0 ± 0.132) Diagnostic Healthy Vs Metastatic p<0.001 Blood 20043080
510 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in Metastatis Diagnostic Healthy Vs Metastatic p<0.0001 Urine 20043080
511 TMPRSS2–ERG mRNA Humans Fusion Positive in Recurrence Prognostic Biochemical recurrence Vs No recurrence p=0.0000000354 Tissue 20068566
512 ERG expression in TMPRSS2–ERG mRNA Humans Upregulated in Fusion (3.07-fold) Prognostic ERG Fusion Vs No Fusion p=3.48E-11 Tissue 20068566
513 CSPG2+ WNT10B+E2F3+CDKN2A+TYMS+TGFB3+ALOX12+CD44+LAF4 mRNA Humans Upregulated with Biochemical Recurrence Prognostic Biochemical recurrence Vs No recurrence Univariate: p=0.0000002; Multivariate: p=0.0270 Tissue 20068566
514 Enhancer of Zeste 2 (EZH2) mRNA Humans Overexpression leads to aggressive behaviour in Cell Lines Prognostic Overexpression Vs No Overexpression in Cell Lines NA Cell Lines 20087897
531 KLK15 (kallikrein-related peptidase) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p = 0.045 Tissue 20473923
538 SPATA19 mRNA Humans Upregulated in PCa (Increased Prostate cancer risk with High expression) Diagnostic Benign Prostatic Hyperplasia Vs Prostate Cancer p<0.0001 Tissue 20682177
539 LEMD1 mRNA Humans Upregulated in PCa (Increased Prostate cancer risk with High expression) Diagnostic Benign Prostatic Hyperplasia Vs Prostate Cancer p=0.012 Tissue 20682177
543 PCA3 mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0; Multivariate: p=0.02 Urine 20957673
544 TMPRSS2: ERG mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0.002; Multivariate: p=0.028 Urine 20957673
547 PCA3 mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0; Multivariate: p=0.02 Urine 20957673
548 TMPRSS2: ERG mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0.002; Multivariate: p=0.028 Urine 20957673
561 C8orf4; TMC5; PDLIM5; JAG1; HOXA9; C4A; STEAP4; HLA-DMB; COL12A1; DHRS8; C10orf137; SLC7A1; PDZRN3; F3; ACER3; POLB; PXDN; PROM2; GUCY1A3; SOX4; mRNA Humans Upregulated (Fold Change): [C8orf4 (5.14 fold); TMC5 (4.83 fold) ; PDLIM5 (4.51 fold); JAG1 (4.36 fold); HOXA9 (4.25 fold) ; C4A (3.98 fold); STEAP4 (3.92 fold); HLA-DMB (3.85fold); COL12A1 (3.81 fold); DHRS8 (3.81 fold); C10orf137 (3.62 fold); SLC7A1 (3.44 fold); PDZRN3 (3.30 fold); F3 (3.26 fold) ; ACER3 (3.17fold); POLB (3.16 fold); PXDN (3.12 fold); PROM2 (3.11 fold); GUCY1A3 (3.10 fold); SOX4 (3.02 fold);] Diagnostic High BMI Tumor Vs High BMI Normal p<0.05 Tissue 21060327
562 ACADL; PHLDA2; GPD1; L; NTAN1; LOC389048; SFN; HSRG1; PAK1IP1; EBP; ANPEP; ANTXR2; COL4A6; LOC400880; RHOU; GREB1; FLJ30428; C3orf14; ZNF532; SCD; PTN; SC4MOL; MAF; NPAL3; CYP3A5; NOV; ALOX15B; LOC399959; VGL-3; INSIG1; Rcan3; Poteg; P704P; EFS; mRNA Humans Downregulated (Fold Change): [ACADL (0.33 fold); PHLDA2 (0.33 fold); GPD1L (0.33 fold); NTAN1 (0.33 fold); LOC389048 (0.32 fold); SFN (0.32 fold); HSRG1 (0.32 fold); PAK1IP1 (0.32 fold); EBP (0.31 fold); ANPEP (0.31 fold); ANTXR2 (0.29 fold); COL4A6 (0.29 fold); LOC400880 (0.29 fold); RHOU (0.29 fold); GREB1 (0.28 fold); FLJ30428 (0.27 fold); C3orf14 (0.27 fold); ZNF532 (0.26 fold); SCD (0.25 fold); PTN (0.24 fold); SC4MOL (0.24 fold); MAF (0.22 fold); NPAL3 (0.22 fold); CYP3A5 (0.21 fold); NOV (0.20 fold); ALOX15B (0.17 fold); LOC399959 (0.17 fold); VGL-3 (0.16 fold); INSIG1 (0.16 fold); Rcan3 (0.15 fold); Poteg (0.14 fold); P704P (0.13 fold); EFS (0.13 fold)] Diagnostic High BMI Tumor Vs High BMI Normal p<0.05 Tissue 21060327
582 GSTP1, BCL2, ADCY4, CACNA1G, LOC63928, and D4S234E mRNA Humans Downregulated Diagnostic Tumor Vs Tumor Adjacent p<0.05 Tissue 21237555
584 SLCO1B1; SLCO1B3; SLCO2A1; SLCO3A1; mRNA Humans Upregulated in CRPC metastases: SLCO1B1 (5.5 fold); SLCO1B3( 3.6 fold); SLCO2A1 (3.2 fold); SLCO3A1 (5.4 fold); Prognostic CRPC metastases versus untreated prostate cancer p<0.053 Tissue 21266523
597 Engrailed-2 (EN2) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p<0.05 Cell Lines 21364037
644 PSMA mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign p=0.016 Urine 21520154
645 PSGR mRNA Humans Upregulted in PCa Diagnostic Prostate Cancer Vs Benign p<0.001 Urine 21520154
646 PCA3 mRNA Humans Upregulted in PCa Diagnostic Prostate Cancer Vs Benign p=0.018 Urine 21520154
647 PSMA + PSGR + PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign NA Urine 21520154
648 PSMA + PSGR + PCA3 + PSA mRNA Humans Differentially Expressed Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml NA Urine 21520154
649 PSMA mRNA Humans Downregulated in PCa Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml p=0.003 Urine 21520154
650 PSGR mRNA Humans Upregulted in PCa Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml p= 0.009 Urine 21520154
651 PCA3 mRNA Humans Upregulted in PCa Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml p=0.025 Urine 21520154
652 PSMA + PSGR + PCA3 mRNA Humans Differentially Expressed Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml NA Urine 21520154
658 PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer p=0.001 Urine 21600800
659 PSA mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate cancer p=0.019 Urine 21600800
660 TMPRSS2:ERG mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer p=0.001 Urine 21600800
661 PSA +PCA3 + TMPRSS2:ERG mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer NA Urine 21600800
662 TMPRSS2:ERG+ PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer NA Urine 21600800
673 Androgen Receptor mRNA Humans Downregulated in PCa Diagnostic Tumor Vs Normal Tissues p=0.018 Tissue 21667031
688 PCA3 mRNA Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
689 PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p=0.04 Urine 21788966
690 AMACR mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p=0.04 Urine 21788966
691 Multiplex Model (PCA3+ AMACR+ SPINK1+ EZH2+ GOLM1+ TRPM8 + MSMB + Serum PSA) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
692 Quadriplex Model (TRPM8 + MSMB+ PCA3+ AMACR) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
693 Triplex Model (TRPM8 + MSMB+AMACR) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
694 Duplex Model (TRPM8 + MSMB) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p=0.01 Urine 21788966
695 AMACR mRNA Humans Upregulated in locally advanced cancers Prognostic localized Vs locally advanced cancers p= 0.044 Urine 21788966
696 EZH2 mRNA Humans Upregulated in locally advanced cancers Prognostic localized Vs locally advanced cancers p= 0.022 Urine 21788966
697 EZH2 mRNA Humans Upregulated in Intermediate and further upregulated in High Risk Group Prognostic Low Vs Intermediate Vs High Risk Group High vs low-risk group patients (P = 0.002), intermediate vs low risk group patients (P = 0.044) Urine 21788966
698 PCAT-1 ncRNA Humans Upregulated in a subset of metastatic and high-grade localized (Gleason score ≥7) cancers Prognostic High grade tumor vs. low grade tumor/non-tumor NA Tissue 21804560
705 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls NA Blood 21832279
760 OPNa (osteopontin -a ) mRNA Humans Upregulated in Cancerous Conditions (PCA: Median: 62.43; BPH: Median: 0.20) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
761 OPNb (osteopontin -b ) mRNA Humans Upregulated in Cancerous Conditions (PCA: Median: 43.47; BPH: Median: 0.50) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
762 OPNc (osteopontin -c ) mRNA Humans Upregulated in Cancerous Conditions (PCA: Median: 200.36; BPH: Median: 0.0) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
763 tPSA mRNA Humans Upregulated in Cancerous Conditions (PCA: Median: 7.51; BPH: Median: 4.15) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Serum 21963599
764 OPNa+OPNb+OPNc mRNA Humans Upregulated in Cancerous Conditions Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
765 OPNa+OPNb+OPNc+PSA mRNA Humans Upregulated in Cancerous Conditions Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
766 OPNc+PSA mRNA Humans Upregulated in Cancerous Conditions Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
767 OPNa (osteopontin -a ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 0.35, Median for GS ≥ 7: 84.54) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p= 0.006 Tissue 21963599
768 OPNb (osteopontin -b ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 3.54, Median for GS ≥ 7: 61.19) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p = 0.003 Tissue 21963599
769 OPNa (osteopontin -a ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 112.06, Median for GS ≥ 7: 526.39) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p= 0.001 Tissue 21963599
786 AMACR+CSTA+HPN+MYO6+LAMB3+ABCC4 mRNA Humans Upregulated: [ABCC4, AMACR, HPN and MYO6]; Downregulated: [CSTA and LAMB3] Diagnostic Tumor Vs Normal Tissues p<0.001 Tissue 22009027
800 PRKAR1A; LRRN3; PCDH17; TTN; LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1;DEFA1; DEFA1; DEFA3; DEFA1; DEFA1; CTSG; DEFA4; ELA2; mRNA Humans Downregulated (0.6-0.82 fold): [PRKAR1A; LRRN3; PCDH17; TTN;] ; Upregulated (0.6 - 1.36 fold): [LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1e;DEFA1e; DEFA1e; DEFA3; DEFA1e; DEFA1e; CTSG; DEFA4; ELA2;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination p< 0.008 Blood 22071976
801 LTB; OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCA; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCA; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1; CAMP; ELA2; DEFA4; DEFA3; DEFA1; DEFA1; DEFA1; DEFA1; mRNA Humans Downregulated: [LTB (1.03 fold)] ; Upregulated (1.04- 2.87 fold): [OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCAe; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCAe; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1e; CAMP; ELA2; DEFA4; DEFA3; DEFA1e; DEFA1e; DEFA1e; DEFA1e;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - Postvaccination p< 0.008 Blood 22071976
802 RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; SNCA; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; ALAS2; CAMP; LCN2; OLFM4; DEFA3; DEFA1; DEFA1; DEFA1; ERAF; CA1; HBD; DEFA1; mRNA Humans Upregulated Postvaccine treatment: [RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; CAMP; LCN2; OLFM4; DEFA3; DEFA1;ERAF; CA1; HBD;] Predictive Short Term Survival Pre Vs Post Vaccination p< 0.008 Blood 22071976
803 LRRN3+PCDH17+HIST1H4C+PGLYRP1 mRNA Humans Downregulated: [LRRN3; PCDH17;] ; Upregulated: [HIST1H4C; PGLYRP1;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination p< 0.008 Blood 22071976
813 TGFβ1 (transforming growth factor beta 1) mRNA Humans Associated with Prostate cancer specific Survival Prognostic disease specific survival Vs no survival p=0.0 Tissue 22113713
814 (IL-7) Interleukin-7 mRNA Humans Associated with Prostate cancer specific Survival Prognostic disease specific survival Vs no survival p=0.03 Tissue 22113713
816 ARHI mRNA Humans Downregulated in aggressive Prostate Cancer (Aggressive:9.6 ± 1.2; Non Agressive: 8.3 ± 2.3 ) Prognostic Agressive Vs Non - Agressive Prostate Cancer p=0.001 Tissue 22117988
822 TDRD1 mRNA Humans Upregulated in Prostate cancer Diagnostic Benign Vs Tumor p<0.05 Tissue 22142399
823 TDRD1 mRNA Humans Upregulated in TMPRSS2-ERG gene fusion (36 fold) compared to benign samples and TMPRSS2-ERG gene fusion compared to non fusion (23 fold). Prognostic Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion TMPRSS2-ERG positive tumors compared to normal (p = 1.77*10^-9) and fusion-negative samples (p = 1.51*10^-9) Tissue 22142399
824 CRISP3 mRNA Humans Upregulated in Prostate cancer Diagnostic Benign Vs Tumor p<0.05 Tissue 22142399
825 CRISP3 mRNA Humans Upregulated in TMPRSS2-ERG gene fusion (37 fold) compared to benign samples, normal and fusion-negative tumor samples (FC = 1.2) Diagnostic Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion TMPRSS2-ERG positive tumors compared to normal tissue (p = 2.2*10-12), normal and fusion-negative tumor samples (p = 0.03) Tissue 22142399
826 CRISP3, AMACR , OR51E2, SPRR2F , TDRD1, F5, ACSM1, C20orf74, GOLM1 , MYC, CACNA1D, SFRP4, TRIB1, GDF15, LRRN1, FOLH1 , PRR16, LUZP2, RRM2, ERG, COL1A1, DNAH5, ZNF417 , SPON2, RICS, HIPK2 , ACACA , TUG1, COQ6 , LARP1, NETO2, FLJ20184, FASN, NEDD4L, LOC286161, MAOA, XPO6, ABCC4, RAB3B, TMEM45B, IMPDH2, DAPK1, LOC100131821 , C19orf48, KIAA1244 , GPI , HIVEP1, NAALADL2, C11orf92, THBS4, MYO6, BAMBI, ZNF462, SPOCK1, REPS2, SGEF, TBC1D16, TRIM36, LBH, AGPAT3, CAMKK2, GCNT1, F2R, BAT2L , LRIG1, GLYATL1 , DDX21, PLA1A, TMEFF2, SLC7A1, KIAA0368, PCDHB13 , UGT2B10 , EEF2 , C10orf137 , MICAL2, BGN, BICC1 , EIF4A1 , STX19, CHD6, ASPN, PTPN13, RAB3IP, ZNF146, BCOR, SH3RF1, TMTC4, ZDHHC9, MS4A8B, UTRN, DIP2B, UAP1, C4A , HDLBP, KIF5C, PMEPA1, GRPR , ZNF217, HUWE1, ZNF417 , AAK1 , CCDC6, BRD2, CRKRS, TP53INP1, ABCA1 , H2BFS , LIG3, PHF12, FAM117B, MED13L, TMEM2, PLA2G7, DICER1, SRRM2, BAGE2 , USP54, MYH10, SLC36A1, SLC7A11, LOC651907 , CREB3L1, ATP13A5 , ATP2B1, ANKRD34B, BAZ2A, C10orf12, POSTN, CALR3 , ZNF828, CS, ERGIC1, BXDC1, EIF4G1, PRKCSH, ABHD2, SIM2, NUFIP2, SPP1, RPL9P11 , HSN2 , JAG1, TPX2, MOSC1, TMEM161B , C4orf18 , BAT2L, DDAH1, NOLC1, ANKRD17, LOC100130958 , CMTM4, APOF, GALNT7, SETD5, HIST1H3B, TSPAN13, EPCAM, MLL, ADAR, EGR1, DNAJC10, MLEC, SEL1L, HYOU1, COL1A2, PSD3, MYO10 , ENC1 , BAT2D1, DDI2 , KDM2A , ENO1, C20orf191 , EP300, ALDH1A3, FAM119A , SLC27A2, C9orf91, TKT, NCL , ABHD2, STK33, ACTG2, IGJ, SLC26A4, SLC39A2, ZNF701 , COCH , BZW1 , CCDC68, PTPLA, VSNL1, GCNT2 , RND3, SCN7A, CYP27A1, CYP3A5 , GJA1, GSTM3, CFL2, C2 , HBB, SPATA6, KRT23, GPR87, MPPED2, HIST1H4C, OGN, LRCH2, C12orf75, NTN4, LOC100188947 , NEFH, SRD5A2, ADAM32, DPT, AZGP1, ACSS3, SLC15A2, PROM1, CACNA2D1, CXCL13, MME, ZNF483, L3MBTL4, APLF , CHRDL1, HIST1H1A, LEPREL1, ARMCX1, ANGPT1, MT1M , DSC3, B3GALT2, SLC22A3, ANO5, MT1G, PCP4, ANXA1 , PLN, EAF2 , ANPEP, TCEAL2 , LTF, PRDM5, LOC100134430 , ATRNL1, KRT15, SPOCK3, PI15, CD177, GDEP, CD38, FLRT3, SLC18A2, AOX1, MSMB, TGM4, OLFM4, SLC14A1, AMY1A mRNA Humans Differentially expressed (Log fold change) [CRISP3 ( 2.93 fold); , AMACR ( 2.85 fold); , OR51E2 ( 2.46 fold); , SPRR2F ( 2.36 fold); , TDRD1 ( 2.31 fold); , F5 ( 2.23 fold); , ACSM1 ( 2.23 fold); , C20orf74 ( 2.05 fold); , GOLM1 ( 2.01 fold); , MYC ( 1.83 fold); , CACNA1D ( 1.73 fold); , SFRP4 ( 1.68 fold); , TRIB1 ( 1.68 fold); , GDF15 ( 1.67 fold); , LRRN1 ( 1.67 fold); , FOLH1 ( 1.66 fold); , PRR16 ( 1.59 fold); , LUZP2 ( 1.58 fold); , RRM2 ( 1.57 fold); , ERG ( 1.57 fold); , COL1A1 ( 1.57 fold); , DNAH5 ( 1.57 fold); , ZNF417 ( 1.56 fold); , SPON2 ( 1.56 fold); , RICS ( 1.55 fold); , HIPK2 ( 1.54 fold); , ACACA ( 1.54 fold); , TUG1 ( 1.51 fold); , COQ6 ( 1.5 fold); , LARP1 ( 1.49 fold); , NETO2 ( 1.49 fold); , FLJ20184 ( 1.48 fold); , FASN ( 1.48 fold); , NEDD4L ( 1.47 fold); , LOC286161 ( 1.46 fold); , MAOA ( 1.45 fold); , XPO6 ( 1.43 fold); , ABCC4 ( 1.43 fold); , RAB3B ( 1.42 fold); , TMEM45B ( 1.42 fold); , IMPDH2 ( 1.39 fold); , DAPK1 ( 1.38 fold); , LOC100131821 ( 1.38 fold); , C19orf48 ( 1.37 fold); , KIAA1244 ( 1.36 fold); , GPI ( 1.35 fold); , HIVEP1 ( 1.34 fold); , NAALADL2 ( 1.34 fold); , C11orf92 ( 1.34 fold); , THBS4 ( 1.33 fold); , MYO6 ( 1.31 fold); , BAMBI ( 1.31 fold); , ZNF462 ( 1.3 fold); , SPOCK1 ( 1.3 fold); , REPS2 ( 1.28 fold); , SGEF ( 1.28 fold); , TBC1D16 ( 1.27 fold); , TRIM36 ( 1.27 fold); , LBH ( 1.26 fold); , AGPAT3 ( 1.26 fold); , CAMKK2 ( 1.25 fold); , GCNT1 ( 1.24 fold); , F2R ( 1.24 fold); , BAT2L ( 1.24 fold); , LRIG1 ( 1.23 fold); , GLYATL1 ( 1.23 fold); , DDX21 ( 1.23 fold); , PLA1A ( 1.22 fold); , TMEFF2 ( 1.22 fold); , SLC7A1 ( 1.22 fold); , KIAA0368 ( 1.22 fold); , PCDHB13 ( 1.21 fold); , UGT2B10 ( 1.21 fold); , EEF2 ( 1.2 fold); , C10orf137 ( 1.2 fold); , MICAL2 ( 1.2 fold); , BGN ( 1.19 fold); , BICC1 ( 1.19 fold); , EIF4A1 ( 1.19 fold); , STX19 ( 1.18 fold); , CHD6 ( 1.18 fold); , ASPN ( 1.18 fold); , PTPN13 ( 1.18 fold); , RAB3IP ( 1.18 fold); , ZNF146 ( 1.18 fold); , BCOR ( 1.17 fold); , SH3RF1 ( 1.17 fold); , TMTC4 ( 1.16 fold); , ZDHHC9 ( 1.16 fold); , MS4A8B ( 1.16 fold); , UTRN ( 1.16 fold); , DIP2B ( 1.15 fold); , UAP1 ( 1.15 fold); , C4A ( 1.15 fold); , HDLBP ( 1.15 fold); , KIF5C ( 1.14 fold); , PMEPA1 ( 1.14 fold); , GRPR ( 1.14 fold); , ZNF217 ( 1.13 fold); , HUWE1 ( 1.13 fold); , ZNF417 ( 1.13 fold); , AAK1 ( 1.13 fold); , CCDC6 ( 1.12 fold); , BRD2 ( 1.12 fold); , CRKRS ( 1.12 fold); , TP53INP1 ( 1.12 fold); , ABCA1 ( 1.12 fold); , H2BFS ( 1.12 fold); , LIG3 ( 1.11 fold); , PHF12 ( 1.11 fold); , FAM117B ( 1.11 fold); , MED13L ( 1.11 fold); , TMEM2 ( 1.11 fold); , PLA2G7 ( 1.11 fold); , DICER1 ( 1.11 fold); , SRRM2 ( 1.1 fold); , BAGE2 ( 1.1 fold); , USP54 ( 1.1 fold); , MYH10 ( 1.1 fold); , SLC36A1 ( 1.1 fold); , SLC7A11 ( 1.1 fold); , LOC651907 ( 1.1 fold); , CREB3L1 ( 1.1 fold); , ATP13A5 ( 1.09 fold); , ATP2B1 ( 1.09 fold); , ANKRD34B ( 1.09 fold); , BAZ2A ( 1.08 fold); , C10orf12 ( 1.08 fold); , POSTN ( 1.08 fold); , CALR3 ( 1.07 fold); , ZNF828 ( 1.07 fold); , CS ( 1.07 fold); , ERGIC1 ( 1.07 fold); , BXDC1 ( 1.07 fold); , EIF4G1 ( 1.06 fold); , PRKCSH ( 1.06 fold); , ABHD2 ( 1.06 fold); , SIM2 ( 1.06 fold); , NUFIP2 ( 1.06 fold); , SPP1 ( 1.06 fold); , RPL9P11 ( 1.06 fold); , HSN2 ( 1.05 fold); , JAG1 ( 1.05 fold); , TPX2 ( 1.05 fold); , MOSC1 ( 1.04 fold); , TMEM161B ( 1.04 fold); , C4orf18 ( 1.04 fold); , BAT2L ( 1.04 fold); , DDAH1 ( 1.04 fold); , NOLC1 ( 1.03 fold); , ANKRD17 ( 1.03 fold); , LOC100130958 ( 1.03 fold); , CMTM4 ( 1.03 fold); , APOF ( 1.03 fold); , GALNT7 ( 1.02 fold); , SETD5 ( 1.02 fold); , HIST1H3B ( 1.02 fold); , TSPAN13 ( 1.02 fold); , EPCAM ( 1.02 fold); , MLL ( 1.02 fold); , ADAR ( 1.02 fold); , EGR1 ( 1.02 fold); , DNAJC10 ( 1.02 fold); , MLEC ( 1.02 fold); , SEL1L ( 1.01 fold); , HYOU1 ( 1.01 fold); , COL1A2 ( 1.01 fold); , PSD3 ( 1.01 fold); , MYO10 ( 1.01 fold); , ENC1 ( 1.01 fold); , BAT2D1 ( 1.01 fold); , DDI2 ( 1.01 fold); , KDM2A ( 1.01 fold); , ENO1 ( 1.01 fold); , C20orf191 ( 1.01 fold); , EP300 ( 1.01 fold); , ALDH1A3 ( 1.01 fold); , FAM119A ( 1.01 fold); , SLC27A2 ( 1.0 fold); , C9orf91 ( 1.0 fold); , TKT ( 1.0 fold); , NCL ( 1.0 fold); , ABHD2 ( 1.0 fold); , STK33 ( -1.0 fold); , ACTG2 ( -1.01 fold); , IGJ ( -1.01 fold); , SLC26A4 ( -1.01 fold); , SLC39A2 ( -1.01 fold); , ZNF701 ( -1.01 fold); , COCH ( -1.02 fold); , BZW1 ( -1.03 fold); , CCDC68 ( -1.03 fold); , PTPLA ( -1.04 fold); , VSNL1 ( -1.04 fold); , GCNT2 ( -1.05 fold); , RND3 ( -1.05 fold); , SCN7A ( -1.05 fold); , CYP27A1 ( -1.05 fold); , CYP3A5 ( -1.05 fold); , GJA1 ( -1.06 fold); , GSTM3 ( -1.07 fold); , CFL2 ( -1.09 fold); , C2 ( -1.09 fold); , HBB ( -1.1 fold); , SPATA6 ( -1.1 fold); , KRT23 ( -1.11 fold); , GPR87 ( -1.11 fold); , MPPED2 ( -1.11 fold); , HIST1H4C ( -1.11 fold); , OGN ( -1.12 fold); , LRCH2 ( -1.12 fold); , C12orf75 ( -1.12 fold); , NTN4 ( -1.12 fold); , LOC100188947 ( -1.12 fold); , NEFH ( -1.13 fold); , SRD5A2 ( -1.15 fold); , ADAM32 ( -1.16 fold); , DPT ( -1.16 fold); , AZGP1 ( -1.16 fold); , ACSS3 ( -1.17 fold); , SLC15A2 ( -1.17 fold); , PROM1 ( -1.18 fold); , CACNA2D1 ( -1.18 fold); , CXCL13 ( -1.18 fold); , MME ( -1.18 fold); , ZNF483 ( -1.19 fold); , L3MBTL4 ( -1.19 fold); , APLF ( -1.21 fold); , CHRDL1 ( -1.21 fold); , HIST1H1A ( -1.23 fold); , LEPREL1 ( -1.25 fold); , ARMCX1 ( -1.25 fold); , ANGPT1 ( -1.26 fold); , MT1M ( -1.27 fold); , DSC3 ( -1.29 fold); , B3GALT2 ( -1.29 fold); , SLC22A3 ( -1.3 fold); , ANO5 ( -1.31 fold); , MT1G ( -1.31 fold); , PCP4 ( -1.32 fold); , ANXA1 ( -1.32 fold); , PLN ( -1.32 fold); , EAF2 ( -1.33 fold); , ANPEP ( -1.35 fold); , TCEAL2 ( -1.39 fold); , LTF ( -1.4 fold); , PRDM5 ( -1.42 fold); , LOC100134430 ( -1.42 fold); , ATRNL1 ( -1.42 fold); , KRT15 ( -1.43 fold); , SPOCK3 ( -1.44 fold); , PI15 ( -1.44 fold); , CD177 ( -1.46 fold); , GDEP ( -1.47 fold); , CD38 ( -1.53 fold); , FLRT3 ( -1.58 fold); , SLC18A2 ( -1.69 fold); , AOX1 ( -1.72 fold); , MSMB ( -1.74 fold); , TGM4 ( -1.76 fold); , OLFM4 ( -1.85 fold); , SLC14A1 ( -1.95 fold); , AMY1A ( -2.11 fold)] Diagnostic Benign Vs Tumor p<0.006857824 Tissue 22142399
833 APOD; C1QTNF3; CD27; CFB; CFH; CLU; CRABP1; DDAH2; FTL; IGSF8; ITIH4l; LGALS3; LYZ; MGAT5; PECAM1; RBP4; RECK; SELENBP1; SLIT2; mRNA Humans (1.358 fold) Upregulated in PCa [APOD (2.803 fold) ; C1QTNF3 (1.100 fold); CD27 (1.183 fold); CFB (3.231 fold); CFH (1.381 fold); CLU (1.638 fold); CRABP1 (1.477 fold) ; DDAH2 (1.152 fold) ; FTL (1.718 fold); IGSF8 (1.358 fold) ; ITIH4l (1.215 fold) ; LGALS3 (4.121 fold) ; LYZ (2.093 fold) ; MGAT5 (1.112 fold); PECAM1 (2.404 fold) ; RBP4 (1.872 fold); RECK (2.569 fold) ; SELENBP1 (1.327 fold) ; SLIT2 (1.848 fold)] Diagnostic Prostate Cancer Vs Normal controls p<0.001 Urine 22194848
882 ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1 LncRNA Humans Differentially expressed (Median Fold Change): [ANRIL (MFD: −1.17 fold); H19 (MFD: 1.32 fold); PCA3 (MFD: 14.3 fold); MALAT1 (MFD: −1.64 fold); PCGEM1 (MFD: 1.75 fold); PTENP1 (MFD: −1.34 fold);] Diagnostic Primary Vs Normal p<0.01 Tissue 22371711
883 ANRIL; H19; PCA3; MALAT1 LncRNA Humans Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.49 fold); H19 (MFD: 1.43 fold); PCA3 (MFD: 4.46 fold); MALAT1 (MFD: -3.33 fold)] Diagnostic Metastatic Vs Normal p<0.01 Tissue 22371711
884 ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1 LncRNA Humans Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.33 fold); H19 (MFD: -1.12 fold); PCA3 (MFD: -3.44 fold); MALAT1 (MFD: -2.63 fold); PCGEM1 (MFD: -4 fold); PTENP1 (MFD: 1.50 fold);] Diagnostic Metastatic Vs Primary p<0.04 Tissue 22371711
887 kallikrein-related peptide 4 (KLK4) mRNA Humans Downregulated in genistein treated patients compared to placebo treated Predictive Treated with Placebo Vs Treated with Genistein (30mg capsule) p=0.033 Tissue 22397815
896 Ring finger protein 19A (RNF19A) mRNA Humans Upregulated in PCa (>2 fold) Diagnostic Prostate Cancer vs healthy controls p = 0.0066 Blood 22493721
903 ERG mRNA Humans Upregulated in TMPRSS2-ERG positive fusion cases Prognostic TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer p<0.0001 Tissue 22505341
904 SPINK1 mRNA Humans Upregulated in TMPRSS2-ERG negative fusion cases Prognostic TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer p=0.03 Tissue 22505341
905 ERG mRNA Humans Upregulated in TERT positive cases Prognostic TERT positive compared to TERT negative in Prostate cancer p=0.016 Tissue 22505341
906 Fusion status of TMPRSS2-ERG and TERT expression mRNA Humans TMPRSS2–ERG and TERT-negative tumors had significantly lower rate of recurrence Prognostic Biochemical Recurrence Free Survival p=0.025 Urine 22505341
918 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer (@ first negative biopsy) [Group A] NA Urine 22564540
919 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer (@ first negative biopsy) [Group B] NA Urine 22564540
934 NACA + CCNB1 mRNA Humans CCNB1 upregulated in Prostate cancer; NACA Downregulated in Prostate Cancer Diagnostic BPC VS BP p<0.05 Tissue 22640805
935 GPR37; SOX4; CCNB1; TOP2A; DLG5; NACA; NR2C2; PDCD5; IDSP1 mRNA Humans Upregulated: [GPR37; SOX4; CCNB1; TOP2A;] Downregulated: [DLG5; NACA; NR2C2; PDCD5; IDSP1] Diagnostic BPC (benign prostates containing PCa) VS BP GPR37 (training: 0.018, testing: 0.003); SOX4 (training: 0.03, testing: 0.03); CCNB1 (training: 0.002, testing: 0.007); TOP2A (training: 0.018); DLG5 (training: p< 0.001, testing: 0.004); NACA (p<0.001, testing: 0.003) ; NR2C2 (training: p<0.001, testing: 0.02); PDCD5 (training: p<0.001); IDSP1 (training: p<0.001) Tissue 22640805
936 PCA3 mRNA Humans Upregulated (RQ = NP: 7.4 Vs LG = 202) Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa <0.005 Tissue 22674214
937 TMPRSS2:ERG Fusion mRNA Humans Upregulated (RQ = NP: 0.6 Vs LG = 11) Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa <0.005 Tissue 22674214
938 PCA3 + TMPRSS2:ERG gene fusion mRNA Humans Upregulated in PCa Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa NA Tissue 22674214
939 TMPRSS2:ERG gene fusion (given that PCA3 test is negative) mRNA Humans Upregulated in PCa Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa NA Tissue 22674214
962 Prostate Cancer Antigen 3 (PCA3) mRNA Humans Upregulated in PCa [No PCa: 32 (13.5–68) Vs PCa 50 (34–83)] Diagnostic PCa Vs No-PCa p=0.001 Urine 22821756
963 PCA3 + phi mRNA Humans Upregulated in PCa Diagnostic PCa Vs No-PCa p=0.001 Urine + Serum 22821756
968 GADD45B; CDKN1A; NLRP1; ERBB3; FMO5; SERINC2; AMFR; DPP4; PGC; YWHAE; EHF; TF; TNFSF10; EIF5A; TGM4; mRNA Humans Upregulated in Relapse: [GADD45B (4.86 fold); CDKN1A (2.65 fold); NLRP1 (1.57 fold)]; Downregulated in Relapse: [ERBB3 (0.55 fold); FMO5 (0.55 fold); SERINC2 (0.43 fold); AMFR (0.41 fold); DPP4 (0.40 fold); PGC (0.38 fold); YWHAE (0.34 fold); EHF(0.33 fold); TF (0.33 fold); TNFSF10 (0.31 fold); EIF5A (0.15 fold); TGM4 (0.03 fold);] Prognostic Relpase Vs No Relapse p<0.05 Tissue 22870216
978 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; genes or ncRNA Humans Upregulated: AOX1-001, RSRC2-017, ABCC4-004, ALK-001, ATP1A1-002, NAMPT-006, RP11-627G23.1-004 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.0 Diagnostic Primary Vs Normal p<0.05 Tissue 22956952
979 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; genes or ncRNA Humans Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1 Prognostic Metastatic Vs Primary p<0.05 Tissue 22956952
980 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; genes or ncRNA Humans Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1 Diagnostic Metastatic Vs Normal p<0.05 Tissue 22956952
981 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; genes or ncRNA Humans NA Prognostic Biochemical Recurrence p<0.005 Tissue 22956952
983 EGFR mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.005 Tissue 22977195
985 PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.0003 Tissue 22977195
986 PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Overall Survival p= 0.02 Tissue 22977195
987 EGFR + PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival NA Tissue 22977195
994 Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) mRNA Humans Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)] Prognostic Biochemical relapse Vs No biochemical Relpase p<0.002 Tissue 23028830
995 Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) + Cell Type Hetrogenity + Gleason Score mRNA Humans Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)] Prognostic Biochemical relapse Vs No biochemical Relpase p<0.002 Tissue 23028830
996 GPX1 mRNA Humans Upregulated in Metatstasis Prognostic Relpase Vs No Relapse p<0.001 Blood 23046102
997 SOD2 mRNA Humans Upregulated in Metatstasis Prognostic Relpase Vs No Relapse p=0.01 Blood 23046102
998 AR mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.001 Blood 23046102
999 Cyclin B mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.007 Blood 23046102
1000 bFGF mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.004 Blood 23046102
1001 2 or more out of (GPX1; SOD2; AR; Cyclin B; bFGF) mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p<0.001 Blood 23046102
1002 ABL2+SEMA4D+ITGAL+C1QA+TIMP1+CDKN1A mRNA Humans NA Prognostic low-risk group Vs high-risk group p<0.05 Blood 23059047
1003 CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.58 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.0000346 Blood 23071848
1004 CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.59 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p=0.0000338 Blood 23071848
1005 FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.61 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.00000285 Blood 23071848
1006 KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.44 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000000182 Blood 23071848
1007 KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.66 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p=0.000000816 Blood 23071848
1008 TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1009 Combination of 6 genes duplexes [CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1010 PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3) + KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1011 PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3)+ KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1020 PCA3 score >= 25 mRNA Humans PCA3 Score upregulated in PCa (No PCa: 24; Pca: 60) Diagnostic PCa Vs No PCA group p<0.001 Urine 23201468
1021 TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene homolog) >= 10 mRNA Humans TMPRSS2-ERG fusion upregulated in PCa (No PCa: 15; Pca: 46) Diagnostic PCa Vs No PCA group p<0.001 Urine 23201468
1022 TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene homolog) >= 10 mRNA Humans NA Prognostic Gleason Score <7 Vs Gleason score ≥ 7 p<0.001 Urine 23201468
1023 TMPRSS2-ERG mRNA Humans NA Prognostic Tumor Stage (T3-T4) p = 0.023 Urine 23201468
1042 Early Growth Response 3 (Egr3) mRNA Humans Upregulated in PCa (5.35 fold) Diagnostic Prostate Cancer Vs Normal Prostate p = 2 x 10^-15 Tissue 23342084
1045 Early Growth Response 1 (Egr1) mRNA Humans Downregulated in Relapse (0.784 fold) Prognostic Relpase Vs No Relapse p = 0.017 Tissue 23342084
1065 PCA3 mRNA Humans Upregulated in Cancerous Conditions (Cancerous: 7.69 Vs Non Cancerous: 7.00) Diagnostic Cancerous Vs Non Cancerous p<0.0005 Tissue 23391636
1066 PCA3 mRNA Humans Upregulated in Stage pT3/4 (1.9 Median fold difference) Diagnostic Stage pT2 Vs Stage pT3/4 p=0.015 Tissue 23391636
1067 KLK15 mRNA Humans Upregulated in Stage pT3/4 (2.71 Median fold difference) Diagnostic Stage pT2 Vs Stage pT3/4 p=0.032 Tissue 23391636
1079 PCA3 mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) p=0.02 Urine 23515404
1080 TMPRSS2:ERG mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) p=0.02 Urine 23515404
1081 PCA3 + TMPRSS2:ERG mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) NA Urine 23515404
1082 PCA3 mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive Vs Negative Biopsy P =0.01 Urine 23515404
1083 TMPRSS2:ERG mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive Vs Negative Biopsy P =0.001 Urine 23515404
1084 PCA3 + TMPRSS2:ERG + PSA mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) NA Urine 23515404
1126 PCA3; GAS5; PVT1; DANCR; PCAT1; MEG3; PRINS; HOTTIP; EGOT; LncRNA Humans Upregulated in PCa: [PCA3; GAS5; PVT1; DANCR; PCAT1;]lDownregulated in PCa: [MEG3; PRINS; HOTTIP; EGOT;] Diagnostic Tumor Vs Normal Tissues p< 0.05 Tissue 23728290
1144 HPN; CLDN3; AMACR; GOLPH2; TRIB1; LOC729677; GDF15; TARP; MYC; LOC731404; ZFP36; SIM2; CTGF; GJB1; CENPN; EGR2; FBP1; KLF4; LUZP2; C8orf4; PDLIM3; CREB3L1; GCNT1; CTPS; PTP4A3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 23813660
1145 SLC14A1; LOC642587; TRIM29; CYP3A5; TP73L; SNAI2; PIK3R1; KRT5; NPAL3; FGFR2; CSTA; CAPG; ITGA2; FER1L3; MEIS2; LGALS3BP; GPRC5B; NEFH; GSTM2; S100A16; MME; EVA1; KRT23; ADD3; GSTP1; mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 23813660
1146 Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;] mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Tissue 23813660
1147 Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;] mRNA Humans Upregulated in PCa Diagnostic Agressive Vs Non Agressive Prostate Cancer NA Tissue 23813660
1155 LASP1 + IQGAP3+ NFIB+ S1PR4+ THBS2+ANO7+ PCDH7 + MYBPC1+ EPPK1+ TSBP+ PBX1+ NUSAP1+ ZWILCH+ UBE2C+ CAMK2N1+ RABGAP1+ PCAT-32 + GLYATL1P4/PCAT-80 + TNFRSF19 mRNA Humans Differentially Expressed Prognostic Metastasis Vs No Metastasis p<0.01 Tissue 23826159
1160 Crystallin, alpha B (CRYAB) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1161 Distal-less homeobox 1 (DLX1) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1162 Serum deprivation response (SDPR) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1163 Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 (KCNMA1) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1164 Prostate Cancer Antigen 3 (PCA3) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1165 Aldo-keto reductase family 1, member C1/2 (AKR1C1/2) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1166 Cyclin-dependent kinase 5, regulatory subunit 1 (CDK5R1) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1167 Claudin 7 (CLDN7) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1168 Activated leukocyte cell adhesion molecule (ALCAM) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1169 RAS, dexamethasone-induced 1 (RASD1) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1175 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No evidence of Maligancy p <0.001 Urine 23861782
1176 Prostate Health Index (phi) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No evidence of Maligancy p <0.001 Serum 23861782
1214 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Urine 24080222
1216 Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) mRNA Humans Upregulated in PCa (4 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p = 0.03 Tissue 24081904
1220 Semaphorin 4F (SF4) mRNA Humans Upregulated (high levels) had increased risk of biochemical recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.0002 Tissue 24097862
1240 Prostate cancer antigen 3 [PCA3] mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer NA Urine 24211598
1241 PCA3 /PSA ratio (PCa antigen 3 [PCA3]) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer NA Urine 24211598
1254 Forkhead Box A1 [FOXA1] mRNA Humans Increased in shorter time to Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.028 Tissue 24292680
1255 ACACA; CDCA3; CEP55; CCNB1; CKS2; DLGAP5; SLC7A1;HMMR; HIG2; LOX; MMP10; MCOLN2; NLN; PDLIM5; PSD3; C20orf74; FAM80A; SDK1; STC2; SOX4; TMEM200A; TFF3; UBE2C; UBE2E3; mRNA Humans Upregulated in PCa (log 2 PCa/Normal): [] Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 24349376
1256 Discs Large Homolog 7 [DLG7] mRNA Humans Upregulated in PCa (log 2 PCa/Normal): [] Prognostic Progression Vs No Progression NA Tissue 24349376
1257 Occludin mRNA Humans Downregulated in: [CAHPV-10 (19.08 fold); DU145 (3.2 fold); PC-3 (4.3 fold)]; Upregulated in LNCaP: (2.2 fold) Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 CAHPV-10 (p= 0.001); DU145 (p=0.003); PC-3 (0.003); LNCaP: (p = 0.001) Cell Lines 24358122
1258 Claudin 1 mRNA Humans Downregulated in: [CAHPV-10 (10 fold); LNCaP: (100 fold); DU145 (2.1 fold); PC-3 (3.8 fold)]; Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 p = 0.001 Cell Lines 24358122
1259 Claudin 7 mRNA Humans Downregulated in: [DU145 (5.3 fold); PC-3 (24.8 fold)];Upregulated in LNCaP: (4.63 fold) Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 DU145 (p=0.004); PC-3 (p= 0.01); LNCaP (p = 0.001) Cell Lines 24358122
1260 Claudin 7 mRNA Humans Downregulated in DU145 and PC-3 Prognostic DU145, PC-3 Vs CAHPV-10 DU145 (p=0.02); PC-3 (p<0.001) Cell Lines 24358122
1261 α-catenin mRNA Humans Downregulated in: [DU145 (2.2 fold); PC-3 (33 fold)]; Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 p<0.001 Cell Lines 24358122
1262 α-catenin mRNA Humans Downregulated in DU145 and PC-3 Prognostic DU145, PC-3 Vs CAHPV-10 p<0.001 Cell Lines 24358122
1263 β-catenin mRNA Humans Downregulated in: [CAHPV-10 (3 fold)] ;Upregulated in [LNCaP: (3.8 fold) DU145 (2.2 fold); PC-3 (2.1 fold)] Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 CAHPV-10 (p= 0.015); DU145 (p=0.001); PC-3 (p=0.001) LNCap: (p<0.001) Cell Lines 24358122
1264 β-catenin mRNA Humans Upregulated in DU145 and PC-3 Prognostic DU145, PC-3 Vs CAHPV-10 DU145 (p=0.006); PC-3 (p=0.001) Cell Lines 24358122
1265 E-Cadherin mRNA Humans Downregulated in: [CAHPV-10 (2.3 fold) ; DU145 (5.6 fold); PC-3 (7.25 fold)] Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 CAHPV-10 (p= 0.004); DU145 (p<0.001); PC-3 (p<0.001); Cell Lines 24358122
1288 F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.001 Tissue 24394557
1289 WNT5B mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.004 Tissue 24394557
1290 VGLL3 mRNA Humans NA Prognostic Overall Survival Vs No Survival p<0.0001 Tissue 24394557
1291 c-MAF-a mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.008 Tissue 24394557
1292 CTGF mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.008 Tissue 24394557
1293 AMACR mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.009 Tissue 24394557
1294 MUC1 mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.025 Tissue 24394557
1295 F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p<0.0001 Tissue 24394557
1296 WNT5B mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p<0.0001 Tissue 24394557
1297 VGLL3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.014 Tissue 24394557
1298 c-MAF-a mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.036 Tissue 24394557
1299 CTGF mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.023 Tissue 24394557
1300 IGFBP3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.013 Tissue 24394557
1301 c-MAF-b mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.019 Tissue 24394557
1302 EZH2 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.018 Tissue 24394557
1303 AMACR mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.049 Tissue 24394557
1304 VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival Univariate: [p<0.0001;] Multivariate:[Group2: p=0.013 Group 1: p<0.0001] Tissue 24394557
1305 Clinical Parameters + VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival NA Tissue 24394557
1306 VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival Group2: [Univariate: p= 0.002; Multivariate: 0.030]; Group 1: p<0.0001 Tissue 24394557
1307 Clinical Parameters + VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival NA Tissue 24394557
1331 UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level mRNA Humans NA Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine + Plasma 24512523
1332 UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level mRNA Humans NA Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 NA Urine + Plasma 24512523
1337 PCAT18 LncRNA Humans Upregulated in PCa (8.8-11.1 fold) Diagnostic Prostate Cancer Vs Normal Prostate p<0.001 Tissue 24519926
1338 PCAT18 LncRNA Humans Upregulated in metastatic Prostatic Cancer Prognostic Localised Vs Metastatic Prostate Cancer p<0.001 Tissue 24519926
1381 BTG2; CDC37L1; COL15A1; COL3A1; EIF2D; FDPS; HIST1H1C; HIST1H2BG; IFT57; IGFBP3; ITPR1; LBH; LOC284801; MARCH5; MED4; MEMO1; MXI1; PTN; RPL23AP53; SACM1L; SIRT1; SNORA20; SRSF3; SYNM; mRNA Humans Poor score with decreased BCR Survival Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 1.45E-21; Validation: p=2.85e-3 Tissue 24713434
1395 GABRE mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant p=0.001 Tissue 24737792
1401 GABRE + miR-224 +miR-452 mRNA + miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1402 GABRE RNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1405 OAZ2 mRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1406 GABRE + miR-224 +miR-452+OAZ2 mRNA + miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1426 PCA3 mRNA Humans Upregulated in PCa Diagnostic Negative Vs Positive Biopsy for PCa p<0.0001 Urine 24803095
1427 PCA3 mRNA Humans Upregulated in PCa Diagnostic Controls Vs Positive Biopsy for PCa p <0.0001 Urine 24803095
1522 Oligophrenin-1 (OPHN1) mRNA Humans Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) Diagnostic Prostate Cancer Vs Non Neoplastic Samples NA Tissue 25170626
1539 Anterior gradient 2 Wild Type (AGR2wt) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue 25237833
1540 Anterior gradient 2 Slice Variant H (AGR2-SV-H) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue 25237833
1541 Anterior gradient 2 Wild Type (AGR2wt) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.001 Urine 25237833
1542 Anterior gradient 2 Slice Variant C (AGR2-SV-C) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p≤0.001 Urine 25237833
1543 Anterior gradient 2 Slice Variant E (AGR2-SV-E) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.01 Urine 25237833
1544 Anterior gradient 2 Slice Variant F (AGR2-SV-F) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.01 Urine 25237833
1545 Anterior gradient 2 Slice Variant G (AGR2-SV-G) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p≤0.001 Urine 25237833
1546 Anterior gradient 2 Slice Variant H (AGR2-SV-H) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p≤0.001 Urine 25237833
1548 STEAP1 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Low Risk PCa (4.45 fold) Diagnostic Low Risk PCa Vs Normal Tissue p = 0.007 Tissue 25248617
1549 STEAP1 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in High Risk PCa (8.15 fold) Diagnostic High Risk PCa Vs Normal Tissue p=0.011 Tissue 25248617
1550 STEAP1 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Metastatic PCa (7.45 fold) Diagnostic Metastatic PCa Vs Normal Tissue p=0.011 Tissue 25248617
1551 STEAP2 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Low Risk Localised PCa (5.77 fold) Diagnostic Low Risk Localised PCa Vs Normal Tissue p=0.022 Tissue 25248617
1552 STEAP2 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Locally Advanced PCa (14.10 fold) Diagnostic Localy Advanced PCa Vs Normal Tissue p=0.003 Tissue 25248617
1564 WISP1 mRNA Humans Upregulated in Metastatic PCa Prognostic Primary Vs Metastatis Prostate Cancer p=0.03 Tissue 31069142
1565 TMEFF2 mRNA Humans Upregulated in PCa (Log 2 Median Centered Intensity) Diagnostic Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer p<0.05 Tissue 31060542
1566 TMEFF2 mRNA Humans Upregulated in PCa (Log 2 Median Centered Intensity) Prognostic Primary/Localised Vs Metastatic/CRPC Prostate Cancer p<0.05 Tissue 31060542
1567 TMEFF2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.0001 Tissue 31060542
1568 BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; mRNA Humans Upregulated in PCa (Log 2 Median Centered Intensity) Diagnostic Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer p<0.05 Tissue 31060542
1569 BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.05 Tissue 31060542
1570 BUB1B+CDC45+CDK1+CENPI+CLSPN+ERCC6L+EXO1+NCAPG+NUSAP1+RAD51+RRM2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.05 Tissue 31060542
1586 AF087978; uc002llc; EF177379; BC013821; uc001pyz; AK024556; AB116553; BC012900; LOC100506303; LOC100506922y; LOC100287482; XLOC_l2_009441; LOC154822; XLOC_010807; XLOC_002335; XLOC_l2_009136; XLOC_002871; ANKRD20A9Py; FLJ20444; XLOC_003734y; LOC100505666; LOC100506411; XLOC_007697; XLOC_003734y; XLOC_l2_000735; LOC100129480; XLOC_007162; LOC100506802; LOC100507025; XLOC_010813; LncRNA Humans Upregulated in PC3 (Log Fold Change) [AF087978 (5.8 fold) ; uc002llc(4.8 fold) ; EF177379(4.3 fold) ; BC01382(3.8 fold)1 ; uc001pyz(3.7 fold) ; AK024556 (3.7 fold) ; AB116553 (3.5 fold) ; BC012900 (3.5 fold) ; LOC100506303(2.6 fold) ; LOC100506922(3.6 fold); LOC100287482 (3.0 fold); XLOC_l2_009441 (3.3 fold); LOC154822 (3.2 fold) ; XLOC_010807(3.5 fold) ; XLOC_002335 (3.4 fold); XLOC_l2_009136(2.1 fold); XLOC_002871 (2.3 fold); ANKRD20A9P ( 2.0 fold) ; FLJ20444 (4.1 fold); XLOC_003734( 4.0 fold); LOC100505666(2.1 fold); LOC100506411(4.1 fold); XLOC_007697(3.4 fold); XLOC_003734y(3.5 fold) XLOC_l2_000735(4.6 fold); LOC100129480(4.5 fold); XLOC_007162(3.1 fold); LOC100506802(3.4 fold); LOC100507025(5.7 fold); XLOC_010813(3.8 fold;] Diagnostic PC3 Cells Vs prostate epithelial cells p<0.05 Cell Lines 25307116
1587 LOC100506303; LOC100506922; LOC100287482; XLOC_l2_009441; LOC154822; XLOC_010807; XLOC_002335; XLOC_l2_009136; XLOC_002871; ANKRD20A9Py; FLJ20444; XLOC_003734y; LOC100505666; LOC100506411; XLOC_007697; XLOC_003734y; XLOC_l2_000735; LOC100129480; XLOC_007162; LOC100506802; LOC100507025; XLOC_010813; LncRNA Humans Upregulated in LNCaP (log fold change): [LOC100506303(5.1 fold); LOC100506922y(4.9 fold); LOC100287482(4.8 fold) ; XLOC_l2_009441(4.7 fold); LOC154822(4.6 fold); XLOC_010807 (4.5 fold) ; XLOC_002335( 4.5 fold) ; XLOC_l2_009136(4.4 fold) ; XLOC_002871( 4.2 fold) ; ANKRD20A9(4.0 fold); FLJ20444(4.0 fold); XLOC_003734(3.8 fold) ; LOC100505666(3.7 fold) ; LOC10050641( 3.5 fold)1; XLOC_007697(3.3 fold); XLOC_003734y(3.2 fold); XLOC_l2_000735(2.8 fold); LOC100129480(2.4 fold); XLOC_007162(2.2 fold); LOC100506802(2.1 fold) ; LOC100507025(2.1 fold) ; XLOC_010813(2.1 fold) ;] Diagnostic LNCaP Cells Vs prostate epithelial cells p<0.05 Cell Lines 25307116
1588 XLOC_001699; XLOC_005327y; LOC400958; XLOC_008559y; LINC00340; XLOC_000495; RPS18; XLOC_012294; XLOC_l2_008560; XLOC_009911y; LncRNA Humans Upregulated in PCa [Log2 (Tumor/Normal)]: [XLOC_001699 (4.3 fold) ; XLOC_005327y (4.1 fold); LOC400958 (3.9 fold); XLOC_008559y (3.7 fold) ; LINC00340 (3.6 fold) ; XLOC_000495 (3.6 fold) ; RPS18(3.3 fold) ; XLOC_012294 (3.3 fold); XLOC_l2_008560 (3.3 fold); XLOC_009911y (3.2 fold); Diagnostic Prostate Cancer Vs Adjacent Normal p<0.05 Tissue 25307116
1589 SPRY4-IT1 LncRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.05 Tissue 25307116
1590 AK024556; XLOC_007697; LOC100287482; XLOC_005327; XLOC_008559; XLOC_009911; LncRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.05 Urine 25307116
1604 Full Length Androgen Receptor (AR-FL) mRNA Humans NA Prognostic Progression-free survival Vs No Progression-free survival p=0.0003 Plasma 31055861
1624 KIF20A mRNA Humans Upregulated in prostate cancer tissues compared with HR: 2.060 Pathways include: Kinesins, Aurora B signaling, Polo-like kinase 1 (PLK1) pathway, M phase pathway, MHC class II antigen presentation Prostate Cancer Vs No Prostate Cancer Diagnostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.8406 (95% CI: 0.6603-0.8256) NA p < 0.0001 1623 NA No NA NA Not validated on independent patient dataset 31031850 2019 CDK1 NA Expression Based mRNA Tissue Humans normal tissues Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1625 CCNB1 mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.0166 Tissue 31031850
1626 BUB1 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1627 CENPA mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1628 AURKB mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0002662 Tissue 31031850
1629 CCNB2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.001469 Tissue 31031850
1630 BIRC5 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0001304 Tissue 31031850
1631 AURKA mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1632 BUB1B mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1633 TTK mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1634 KIF20A mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1636 CDKN3 mRNA Humans Upregulated in prostate cancer tissues compared with HR: 2.451 Pathways include: T cell receptor regulation of apoptosis Biochemical recurrence Vs No Biochemical Recurrence Prognostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.6493 NA p =0.0002558 1635 NA No NA NA Not validated on independent patient dataset 31031850 2019 KIF2C NA Expression Based mRNA Tissue Humans normal tissues Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1637 NCAPG mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1638 CDCA8 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0001771 Tissue 31031850
1641 TGM4; SOSTDC1; MPO; SPRR1A; KLF4; RNU3B1; RNU3B3; RNU3B4; MT-ATP6; MT-ATP8; TMEM170A; LYNX1; IFNL3; PPP1R3G; GPR15; UGT2A3; MED13L; DNAJC10; NPY; XIST; LST1; WNT9A; LRRN3; GPR45; IFIT1; YWHAQ; KIR3DL1; EPPIN; CRLF1; MAL2; MAP3K15; H1FX; mRNA Mice Upregulated in prostate cancer tissues compared with NA Pathway include: Genes were related to 12 pathways: (i) Aryl hydrocarbon receptor (AHR) signaling, (ii) Bone metamorphosis signaling, (iii) Wnt/GSK-3β signaling, (iv) Glucocorticoid receptor signaling, (v) Immune cell signaling, (vi) Gas signaling, (vii) iNOS signaling, (viii) Hypoxia signaling, (ix) Wnt/β-catenin signaling, (x) Cancer metastasis signaling (xi) p38MAPK signaling, and (xii) Oxidative phosphorylation TRAMP mice Vs Non-Transgenic Mice Diagnostic Twenty week old TRAMP mice and non-transgenic littermates tissues were harvested NA NA NA NA p<0.05 1640 Microarrays No NA NA Validated on human patient cohort 30972102 2019 TOX4; RPL38; LSM12; RPL5; HAX1; ALPI; TCTE3; RPL7; MRTO4; HDAC1; UBE2H; KRT26; TNFSF10; DPPA2; PNLDC1; MRPS11; PFDN6; STOML2; VDAC1; RPS8; TDGF1; UBE2E2; GKAP1; RPL10A; RPS15; UMOD; RPL9; RPL30; NPNT; NR1I2; KRTAP16-1; H3F3A; H3F3B; MRPL34; CSE1L; ST6GALNAC1; UBE2Q2; RPS17; RPL35; GMCL1; NIP7; MSL2; EIF4A1; LASP1; LUZP4; EIF1AD; TUBB3; RPL34; RPL17; RPL23; RPL28; KIR3DL2; LMO2; NA; AOC3; H2AFZ; RPL37; TMSB10; AMY2A; AMY2B; PPIA; PPIH; BEGAIN; NT5C3A; RPS28; RPL27; IL24; COPS9; NEK2; SOCS2; UBL5; UBE2D3; VHL; RPL23A; AICDA; LDHA; CNEP1R1; RPL29; SPCS1; RPL41; SP110; PMP22; ARCN1; UQCRB; SLC25A19; UBE2N; SNRPE; ACKR1; RPL21; LEFTY2; RPL31; RPL35A; RPL7A; RPL39; NACA; SP140; MRPL23; VDAC3; VDAC1P5; ATP5L; DIMT1; GMCL1P1; ARFGAP2; RPL22;' NA Expression Based mRNA Tissue Mice normal tissues Diagnostic TRAMP mice Vs Non-Transgenic Mice p<0.05 Tissue 30972102
1642 ATP5L; ARFGAP2; DIMT1; GMCL1; MRPL34; RPL22; SP140; VDAC3 mRNA Mice Upregulated in Gleason Grade 5 Diagnostic TRAMP mice Vs Non-Transgenic Mice p<0.01 Tissue 30972102
1643 KLF4; MPO; SOStdc1; SPRR1A; TGM4 mRNA Mice Downregulated in TRAMP Diagnostic TRAMP mice Vs Non-Transgenic Mice p<0.01 Tissue 30972102
1644 TNFSF; RPL22; EIF4; SLC2A; LMO2/3; KRT; RPS21; RPS19; RPL21; NEK; PPP1R3; mRNA Humans Upregulated in TRAMP Diagnostic prostate cancer vs. benign prostate p<0.05 Tissue 30972102
1645 GPR15; GPR45; TME; TGM4; KLF4; LRRN3; WNT; SPRR1A; TMEM; mRNA Humans Upregulated in TRAMP Diagnostic prostate cancer vs. benign prostate p<0.05 Tissue 30972102
1657 MMP2 (Matrix Metalloproteinase-2) mRNA Humans NA Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30917169
1658 BASP1 (Brain Abundant Membrane Attached Signal Protein 1) mRNA Humans Downregulated in High Grade PCa Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30917169
1659 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in High Grade PCa Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30911973
1660 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Downregulated in PCa Prognostic Normal Prostate Vs T2 PCa Vs T3+T4 PCa p<0.001 Tissue 30911973
1661 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in PCa Prognostic Normal Prostate Vs Gleason Score 6 Vs GS 7 VS GS 8 Vs GS 9+GS10 p<0.001 Tissue 30911973
1662 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in PCa Prognostic Disease Free Survival Vs No Disease Free Survival p=0.0365 Tissue 30911973
1663 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in T2 PCa and T3+T4 PCa Diagnostic Normal Cell Lines Vs PCa Cell Lines p<0.001 Cell Lines 30911973
1664 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in GS 6,7,8,9+10 Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30911973
1694 TTTY15-USP9Y mRNA Humans Upregulated in PCa Diagnostic Positive Vs Negative Biopsy p<0.001 Urine 26008593
1695 TTTY15-USP9Y + PSA mRNA Humans Downregulated in Gleason Pattern 4 and 5 Diagnostic Positive Vs Negative Biopsy p<0.001 Urine 26008593
1696 TTTY15-USP9Y mRNA Humans Downregulated in Gleason Upgrade Patients Diagnostic Positive Vs Negative Biopsy p<0.001 Urine 26008593
1729 SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1; mRNA Humans Upregulated in PCa: (PCa: 39.68 ± 30.00; No PCa: 15.04 ± 7.11) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30286759
1730 EMX2OS; LINC02137; LINC01116; LINC00839; AL161645.1; AC012123.1; AL354793.1; LINC02385; HOXB‐AS3; AC005674.1; LncRNA Humans Upregulated in High Risk PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30286759
1732 SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1; mRNA Humans Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;] Prognostic High Risk Vs Low Risk PCa p=0.00822 Tissue 30286759
1770 PCA3 mRNA Humans Upregulated in Stage T3-T4 Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1771 hK2 mRNA Humans Downregulated in Stage T3-T4 Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1822 BUB1 mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1823 TPX2 mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1824 NCAPG mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1825 UBE2C mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1826 MELK mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1827 CCNA2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1828 CCNB1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1829 CDK1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1830 E2F2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1831 DLGAP5 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1832 TMEM206 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1833 CDKN3 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1834 SHMT2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1835 SRD5A2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1836 CSRP1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1837 PGM5 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1838 NFIB mRNA Humans Downregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1839 HEATR5B (HEAT repeat containing 5B); DDC (Dopa decarboxylase, transcript variant 6); TAS1R3 (Taste 1 receptor member 3); XIAP (X-linked inhibitor of apoptosis, transcript variant 2); mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30890858
1840 GABPB1-AS1 (GABPB1 antisense RNA 1); DDC (Dopa decarboxylase, transcript variant 6); HEATR5B (HEAT repeat containing 5B); CARD11 (Caspase recruitment domain family member 11, transcript variant 2); mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30890858
1841 GABPB1-AS1 (GABPB1 antisense RNA 1); KRT5 (Keratin 5); NCS1 (Neuronal calcium sensor 1, transcript variant 2); COL17A1 ( Collagen type XVII alpha 1 chain); ANXA1 (Annexin A1); LGALS3BP (Galectin 3 binding protein); mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30890858
1842 MT1IP (Metallothionein 1I, pseudogene (MT1IP), transcript variant 1); TRPT1 (tRNA phosphotransferase 1 (TRPT1), transcript variant 6); CHFR (Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase (CHFR), transcript variant 2); ZNF830 (Zinc finger protein 830); REXO1L2P (RNA exonuclease one homolog (S. cerevisiae)-like 2); SLC25A21 (SLC25A21 antisense RNA 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T1C Vs T2 p<0.05 Tissue 30890858
1843 FXR2 (Fragile X mental retardation, autosomal homolog 2); GADD45GIP1 (Growth arrest and DNA-damage-inducible, gamma interacting protein 1); STX4 (Syntaxin 4, transcript variant 1); CALCOCO2 (Calcium binding and coiled-coil domain 2, transcript variant 1); BEST4 (Bestrophin 4); URI1 (Prefoldin-like chaperone, transcript variant 3); DCP2 (Decapping mRNA 2, transcript variant 3); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2 Vs T2a p<0.05 Tissue 30890858
1844 RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); SIRPA (Signal-regulatory protein alpha (SIRPA), transcript variant 3); COMP (Cartilage oligomeric matrix protein); SOD3 (Superoxide dismutase 3, extracellular); DIDO1 (Death inducer-obliterator 1, transcript variant 3); PRELP (Proline/arginine-rich end leucine-rich repeat protein, transcript variant 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2a Vs T2b p<0.05 Tissue 30890858
1845 BGN (Homo sapiens biglycan); RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); USP21 (Ubiquitin-specific peptidase 21, transcript variant 3); NR1D1 (Nuclear receptor subfamily 1 group D, member 1); ANGPTL2 (Angiopoietin-like 2); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2b Vs T2c p<0.05 Tissue 30890858
1846 SMAP2 (Small ArfGAP2 (SMAP2), transcript variant 2); TMSA (Prothymosin, alpha (PTMA), transcript variant 1); YY1AP1 (YY1 associated protein 1 (YY1AP1), transcript variant 6); DOCK9 (Dedicator of cytokinesis 9 (DOCK9), transcript variant 2); KITLG (KIT ligand (KITLG), transcript variant b); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2c Vs T3a p<0.05 Tissue 30890858
1847 FAM133DP (Family with sequence similarity 133 member D pseudogene); SAMM50 (Sorting and assembly machinery component 50 homolog, protein coding); OR4F13P (Olfactory receptor family 4 subfamily F member 13 pseudogene); mRNA Humans Differentially Expressed Prognostic Tumor Stage T3a Vs T3b p<0.05 Tissue 30890858
1848 IKZF3 (IKAROS family zinc finger 3 (Aiolos), transcript variant 12); USP13 (Ubiquitin-specific peptidase 13 (isopeptidase T-3)); CLASP1 (Cytoplasmic linker associated protein 1, transcript variant 3); CEP112 (Centrosomal protein 112kDa, transcript variant 3); TSEN15 (tRNA splicing endonuclease subunit, transcript variant 1); FLVCR2 (Feline leukemia virus subgroup C cellular receptor family, member 2,transcript variant 2); GOLGA8B (Golgin A8 family, member B, transcript variant 1); ZNF438 (Zinc finger protein 438, transcript variant 1); SCARNA22 (Small Cajal body-specific RNA 22); LPPR1 (Lipid phosphate phosphatase-related protein type 1, transcript variant 2); PTGFR (Prostaglandin F receptor (FP), transcript variant 1); NREP (Neuronal regeneration related protein, transcript variant 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2c Vs T3/4 p<0.05 Tissue 30890858
1876 PD-L2 (Programmed death ligand 2) mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p=0.01 Tissue 30321406
1877 PD-L2 (Programmed death ligand 2) mRNA Humans Methylated in PCa Prognostic Distant Metastatic Free Survival Vs No DMFS Survival p=0.01 Tissue 30321406
1878 PD-L2 (Programmed death ligand 2) mRNA Humans Upregulated in PCa: []; Downregulated in PCa: [] Prognostic Prostate Cancer Specific Survival Vs No PCSS Survival p<0.001 Tissue 30321406
1906 AFP; AKR1C1; AKR1C3; AKR1C4; C1orf229; C5orf28; C5orf34; CCNE1; DNMT1; E2F3; ENSA; FBXO4; G6PD; KPNA2; LETM2; LGSN; MRPS30; OPLAH; OR4K15; OR4L1; PAIP1; SKP1; SPEF2; WDR70; ZNF124; ZNF280A; ZNF324B; ZNF669; ZNF695; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1907 ANO7; NSA2; BOK; PDE8B; CECR6; PER3; CNNM1; PPP1R7; CNTNAP3; SCAMP1; COX15; SEMA4G; DMGDH; SLC7A8; DUSP1; TMEM18; EPHA7; TRIM8; FAM20C; TSLP; FOXC1; WDR41; ZNF658; GABRG3; GLB1L3; GLOD4; KCNMB1; LOC100128239; LOXL4; MTERFD2; NCAM1; NDN; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1908 ADAM12; AURKA; AURKB; C7orf49; CDCA8; CENPF; CIT; DNMT3B; DYRK2; FANCD2; FGD1; GDAP1; GPI; GTSE1; HNRNPUL1; IPO9; KIF23; LIG1; NCAPH; NHSL1; PEG10; SKP2; TMEM65; TOP2A; TPX2; UBE2T; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1909 ALDH1A3; APH1B; ATAD1; CTBS; CTSO; DHRS7; ESR1; FOXC1; MEIS2; NR4A1; PDE8B; RPS27L; SEC62; SPCS3; ZMAT1; mRNA Humans Upregulated in Metastatic PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717